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ABSTRACT 
GENGBEI SHI. Engineering oxygen transport for improving cell performance in hepatic 
devices (Under the direction of Dr. ROBIN N. COGER and Dr. CHARLES Y. LEE) 
The bioartificial liver (BAL) advancing medical technology aims to provide 
temporary liver substitution for patients in dire need of liver transplants and also for drug 
development. Yet despite nearly fifty years of development, the approval for this medical 
device from U.S. regulatory agencies (e.g., Food and Drug Administration) is still 
pending. The reasons for this have both clinical and fundamental aspects. Current clinical 
trial data does not convincingly demonstrate a higher survival rate of patients that 
received BAL treatment than non-BAL treated control. This issue may be attributed to 
the fundamental fact that, as a medical bioreactor, BALs still lack the effectiveness at the 
level of the natural liver. As oxygen (O2) is a key substance to determine efficiency of the 
hepatocytes housed in the BAL, intensifying the O2 conditions within the BAL cellular 
space will elevate overall BAL performance. This proposition has been substantiated by 
several studies. With higher efficiency the BAL may increase the liver patients’ survival 
rate, benefit new drug development, and may ultimately attain the government approval 
in the U.S. 
The work of this doctoral study focuses on methods of enhancing O2 transport 
into three-dimensional (3D) customized hepatic devices. Firstly, enriched O2 conditions 
were established within customized hepatic systems by applying an inert organic 
compound – perfluorocarbon (PFC). The PFC-treated hepatic cells demonstrated high 
cytochrome P450 (CYP 450) function performance especially when 3D gelatin sponge 
were used as the scaffold. They also exhibited less glucose consumption. Next the 3D 
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gelatin sponge scaffold was then characterized in a computational fluid dynamics (CFD)-
based simulation to clarify the reasons for the performance improvement. The results of 
this simulation also suggest that using the new 3D cellular scaffold is an effective method 
for addressing the O2 delivery problem previously reported for a novel BAL design, the 
four quadrant bioreactor (4QB) when using the 4QB for the support of larger cell 
numbers. Lastly, the effects of a previously custom designed flow device and the gelatin 
sponge scaffold, on the drug metabolism of rat primary hepatocytes (RPHs) were 
evaluated. The key results from the drug metabolism tests were confirmation of the 
benefits of combining the 3D gelatin sponge scaffold and flow condition in increasing the 
hepatocytes drug metabolism enzyme performance. Surprisingly, the results also 
demonstrated the suppression of the RPHs drug metabolizing ability in flow devices and 
relevant analysis to this phenomenon was also conducted. 
This doctoral study has thus provided valuable information on experimental and 
numerical approaches for improving the fundamental performance of future BAL designs. 
It mainly highlights that in BALs, the 3D cell cultures and efficient flow perfusion are 
key to O2 delivery for the scaffold interstitial region (extracellular space). The work thus 
helps moving toward their development one step closer to establish the future clinical 
trial and industrial application of BAL devices.  
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CHAPTER 1: INTRODUCTION 
Liver is the largest internal organ in human body[1] that performs multiple 
essential functions to sustain an individual’s life[2]. For example, it synthesizes albumin 
which is a protein in serum modulating blood oncotic pressure[3], produces urea to 
cleanse ammonia as part of human body nitrous metabolism, secretes bile to facilitate 
fatty acid digestion, composes or decomposes glucose to store or release energy, 
detoxifies heavy metal ions and xenobiotics such as drugs and toxins[4], et cetera. These 
vital functions are vulnerable to liver injury and chronic or severe liver diseases, 
including hepatitis, cirrhosis or hepatoblastoma. When these pathological disruptions 
overwhelm the liver recovery rate, failure of this organ may occur. A devastating case is 
the fulminant hepatic failure (FHF, also: Acute Liver Failure), prognosis of which is 
difficult and has more than 50% mortality [5, 6]. Due to the dangerous situation that 
sepsis and multiple organ failure could be triggered via FHF, it is imperative to take all 
possible treatments to save the patient using immediate and effective methods.  
To date, the most effective therapy to cure liver failure is to perform the 
orthotopic liver transplant (OLT)[5]. This requires one transplant recipient ideally to have 
one matched liver donor. However, the shortage of suitable liver donors continues to 
exclude this option for many liver patients [6, 7]. The discrepancy between number of 
donors and the patients is huge: based on OPTN (Organ Procurement Transplantation 
Network) data as of July 25, 2012 for United States, there are 15,997 patients on the liver 
transplant waiting list nationwide, while total patients successfully received liver 
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transplant surgery during year 2011 were merely 6,932. Animal liver (e.g., porcine liver) 
has greater availability and it seems to be a solution for this gap. However, 
transplantation across different species raises the regulatory agency’s concern of graft 
biocompatibility and xenozoosis[8], leaving the problem unsolved. 
 
 
FIGURE1.1 Natural liver structure and several configurations of popular BALs, 
comparisons of their cell number, density (in terms of “cell number/blood or medium 
volume”), transport area and cell fraction on surface. Reproduced from [9]. 
 
 
 
This medical challenge drives scientists and engineers to find an alternate solution 
to bridge patients who are waiting for liver replacement, or their own liver to recover. 
Such an artificial organ surrogate must firstly mimic natural liver functions at competitive 
levels. It should also have stable manufacturability and independent of limited human 
liver resources[8]. Depending on whether there are biologically viable cells present, this 
type of “hepatic assist device” (or “liver support system”) can be divided into two 
subgroups: artificial liver devices, or bioartifical liver devices (BALs). For the cell-free 
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artificial liver, dialysis, filtration and adsorption are mainly the techniques that had been 
used for toxin clearance. Because of its many shortcomings (e.g., causing thrombocyte 
loss and coagulation disorder, unable to remove protein-bound or hydrophilic toxins, 
unable to perform synthetic function [10, 11]), research advanced to develop a more 
complicated, cell-encapsulated system – the BALs. Since cells are present in BALs, such 
devices do not only have the ability to perform better detoxification, but they also can 
achieve synthetic and metabolic functions. 
Various BAL prototypes have been fabricated, where designs feature direct 
perfusion, flat membrane, or hollow fiber exchange (Fig. 1.1). Some promising 
candidates started to enter the stage of clinical evaluation and/or industrial collaboration. 
These milestones include the HepatAsssist™ device (Arbios Systems Inc., Allendale, 
NJ ), the Extracorporeal Liver Asssist Device (ELAD
®
) (Fig. 1.2), the Bioartificial Liver 
Support System (BLSS™), and the Academic Medical Center Bioartificial Liver (AMC-
BAL) [12]. Nevertheless, none of these BAL has successfully earned FDA approval. 
Thus far, the available clinical trial reports indicate that the designs failed to substantiate 
a significant improvement in FHF patients survival rate [12]. Limitations in the 
functional levels that a single device can achieve are considered one of the common 
reasons to this result. This may be due to the limited cell mass that each device can 
accommodate compared to the capacity of the natural liver (see total cell number 
comparison in Fig. 1.1). Given the limited space and cell mass that a single therapeutic 
device can house, the individual cell’s mean efficiency determines the whole BAL’s 
output. 
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FIGURE1.2 The hollow fiber type BAL ELAD
®
 by Vital Therapies Inc. (San Diego, 
CA). Using C3A hepatoma cell line, four of such cartridges with about total 800 g 
hepatocytes [11] were used in a pilot clinical trial starting from 2007 and containing 49 
patients in China [12]. Image courtesy: Vital Therapies Inc. official website. 
 
 
 
Recalling that the liver is the main site for drug metabolism in the human body, 
pharmaceutical industries will also benefit from successful BALs[13-15]. Conventional 
drug screening relies heavily on in vitro static multi-well plate cell culture and animal 
models. However, though effective in phase I drug metabolism, static primary hepatocyte 
cultures lack further predictability in phase II drug metabolism and clinical trials, partly 
because human physiological environment such as three-dimensional (3D) cell 
architecture, blood flow perfusion, and signal transductions from extrahepatic organs are 
absent in this simple model [16]. While animal models (rodents, pigs, monkeys etc.) with 
integral physiological systems are applied, they do not guarantee successful screening 
due to the genetic difference. Both conventional screening methods have cases that failed 
in the later stage drug developing pipeline, resulting costly withdrawal of drug 
candidates[8, 16]. 
BALs that integrate hepatic cells (either hepatocytes alone, or multi-type co-
culture) are designed to perform drug clearances that mimic the natural liver and its 
preliminary drug screening effectiveness was demonstrated by several studies [14, 17, 
18]. The effectiveness could be attributed to BAL’s many features that are absent in other 
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methods: for example, static plate culture using in conventional drug screening does not 
have blood perfusion-like flow condition, which encourages hepatocytes functionality. 
Besides, BAL’s 3D configuration easily enables the multi-cell type co-culture as in 
natural liver, which is important to regulate hepatcoytes function (e.g., co-culturing 
Kupffer cells which mediates hepatocytes functioning via cytokine)[19, 20]. Minimally, 
BALs as drug testing devices should help predict the cytotoxicity of drugs and the long-
term goal focuses predicting hepatoxicity (organ-level). It is believed that with further 
optimization and experimental efforts, the BALs will emerge and recognize as cost-
effective in vitro drug testing devices. One example of a product candidate is the multi-
well plate BAL device with pneumatic force-driven flow [16, 21] that is currently 
developed for commercialization by HemoShear, LLC (Charlottesville, VA). 
Regardless of its medical or pharmaceutical application, the BAL’s functional 
output level is the key to success. In the natural liver, hepatocytes are in spheroidal shape 
and attached to surrounding extracellular matrix [22]. For many comprehensive 
metabolic tasks they have an aerobic profile with high oxygen (O2) uptake rates (OUR) 
[23]. Molecular O2 is essential as it mediates many fundamental aspects of liver 
metabolism [24]. It is the electron receptor in phosphorylation cycles that provides 
energy[25]. O2 is also the oxidant for the key step of drug and steroids hydroxylation that 
facilitates drug excretion[25, 26]. O2 delivery to hepatocytes is achieved by the natural O2 
carrier – hemoglobin – within erythrocytes, the highly organized hepatic sinusoids 
architecture (Fig. 1.1: hepatic lobule) and hepatic vasculature. The hepatic cellular 
component as BALs functioning portion also has high O2 demand. Besides 
aforementioned O2 importance, increased O2 also magnifies hepatocytes attachment and 
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spreading area of in vitro culture [27]. BAL mainly used aqueous medium in circulation 
for nutrient and O2 supply, whereas the aqueous medium has a low O2 solubility[28] and 
O2 also has a short diffusion distance within[29, 30]. Artificial vascularization in 3D 
tissue equivalent of BAL could help better O2 delivery. But this technique is a challenge 
too[31]. Thus, O2 transport in current BALs is still inadequate and far from clinical 
use[32]. Helping to solve this problem becomes the objective of this dissertation. 
In this dissertation, the functional responses and viability of HepG2/C3A 
hepatoblastoma cell line and primary rat primary hepatocytes (RPH) at different O2 levels 
in flow-perfused 3D cultivation were investigated. Also, the underlying O2 interstitial 
transport in conventional cell scaffold and its replacement have been numerically 
simulated to reveal the material-dependent mechanistic control for O2. Specific to each 
chapter, in CHAPTER 2 and 3, the O2-dissolving capability of a commercial 
perfluorocarbon O2 carrier “Oxycyte
®
” has been characterized and it was supplemented 
to 3D thick flow-perfused C3A hepatoblastoma cell line culture. Chapter 2 results 
demonstrated that PFC-medium mixture with different PFC volume fractions can 
dissolve different O2 contents. Chapter 3 results demonstrated that the PFC supplemented 
medium allowed each C3A cell to consume less glucose while synthesizing the same 
level of albumin as control in dynamic condition. The same condition – PFC-medium and 
dynamic flow condition – also encouraged cell population growth (7 times of PFC-free 
control at endpoint) under toxic drug inducer condition for cytochrome P450 activity 
assay. In CHAPTER 4, O2 transport in the four quadrant bioreactor (4QB) was 
computationally simulated via ANSYS FLUENT
®
. The primary goal of the simulation 
was to identify how manipulating the scaffold affects O2 diffusion to the RPHs 
 
 
7 
maintained in the 4QB on a computational basis. Results of this chapter indicate that 
while O2 condition in 4QB at housing double cell population becomes inadequate, 
replacing the scaffold from collagen gel to gelatin sponge as well as doubling the flow 
rate can improve the O2 level cells in 4QB receive. In CHAPTER 5, the use of two 
hepatic 3D bioreactors as initial drug screening devices was explored. Activities of two 
key drug metabolism enzymes (DMEs): ethoxycoumarin-O-deethylase (ECOD) and 
ethoxyresorufin-O-deethylase(EROD) of RPHs for each device were investigated in 
various culture configurations. These culture types include conventional multi-well 
sandwich, static 3D and 3D flow-perfusion cultures. Results of this chapter demonstrated 
the effectiveness of gelatin sponge and flow device on DMEs activities of RPH, and also 
suggested potential overdosing effects of medium volume changed in different flow 
devices compared to that in static culture. Overall, this dissertation explored three general 
ways to enhance O2 transport for hepatic cells functional improvement: (1) by ECM 
manipulation (e.g., replacing collagen gel with gelatin sponge) for allowing more O2 
delivered to cellular space, (2) by medium supplementation (e.g., adding PFC to aqueous 
medium) for carrying more O2 in hepatic device circulation, and (3) by flow device 
design to regulate flow pattern and deliver O2 into interstitial space more effectively (e.g., 
ineffective circumventing flow pattern in plate device compared to effective perfusion 
flow pattern in tube device). The methods investigated in this dissertation can be 
modified and applied to more other BAL devices, for their functional improvement and 
potentially better therapeutic efficacy. 
 
CHAPTER 2: THE OXYGEN CAPCITIES OF PERFLUOROCARBON-
SUPPLEMENTED MEDIUM AT DIFFERENT CONCENTRATIONS 
2.1 Introduction 
As seeking engineering solutions to improve O2 availability in BALs, 
perfluorocarbons (PFCs) are of great interest. PFCs are a family of highly inert 
compounds that were originally synthesized during World War II for the Manhattan 
project by replacing all hydrogen (H) atoms with fluorine (F) atoms [and possibly other 
halogen atom such as bromine atom in PFOB (perflubron)
*
] in hydrocarbons (CnHm). 
Because PFCs have extraordinary O2 solubility due to their molecular affinity for O2 [33-
38], they are utilized in clinical applications [39, 40] such as the partial liquid ventilation 
for patients with respiratory disease [41]. They have even been used in diagnostic 
imaging [42]. When used in in vitro cell cultures, a variety of effects have been reported: 
for non-hepatic cell cultures, one of the PFCs – PFOB – “permanently inhibited human 
fibroblast cell proliferation and decreased mitochondrial activity” when added to culture 
medium[43]. In addition PFOB was found to “attenuate oxidative damage” for rat 
pulmonary artery endothelial cells[44]. Another PFC – perfluorodecalin
†
 – was shown to 
have positive effects on the human Hela cell line [45]. In hepatic culture studies of rat 
primary hepatocytes (RPH) cultivated in PFOB-embedded collagen gel, albumin 
secretion, ureagenesis (for the first 24hours) and CYP1A1 activity of were improved [34]. 
Contrastingly, the glycolytic activities of porcine primary hepatocytes (PPH) treated by 
                                                        
i. * PFOB (perflubron): perfluorooctyl bromide, C8F17Br 
ii. † perfluorodecalin: C10F18 
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PFOB in a bioreactor were lower than its control [46]. When the HepG2 hepatoblastoma 
cell line was treated by PFTBA
‡
-PFOB blend, increased cell growth rate and improved 
glucose utilization were discovered[36]. It was also reported that HepG2 cells had 47-
104% higher metabolic activity in PFOB-encapsulated alginate matrix[47]. The promise 
of these studies founded the basis for investigating the effects of a PTBCH
§
-based, 
second generation O2 carrier “Oxycyte
®
” on hepatic cells as a possible way to further 
enhance O2 transport in BALs. To achieve this, it was first necessary to characterize its 
O2 dissolution profile. 
2.2 Materials and Methods 
2.2.1 PFC Fraction and O2 Concentration Calibration 
The Oxycyte
®
 PFC emulsion (Oxygen Biotherapeutics, Durham, NC, formerly 
“Synthetic Blood International”, Costa Mesa, CA) contains 60% (w/v) PTBCH plus other 
supplements (Tab. 2.1, because PFCs are hydrophobic and thus immiscible in water, for 
use they are emulsified by surfactant, e.g., egg phospholipid). Previously this 
commercially prepared PTBCH product was used in treatment for rat brain injury [48], or 
as the perfusate in cardiopulmonary bypass machines [49, 50]. Positive effect of rat 
cognitive function improvement was reported, but adverse effect such as increased rat 
inflammatory reaction did appear too. 
  
                                                        
iii. ‡ PFTBA : perfluorotributylamine , C10F21N 
iv. § PTBCH: perfluoro-t-butylcyclohexane, C10F20 
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TABLE 2.1. Percentage of main ingredients in Oxycyte
®
[51]. 
Essential Oxycyte
®
 ingredients Function % (w/v) 
PTBCH effective ingredient 60 
egg yolk phospholipid surfactant/emulsifier - 
 
 
 
TABLE 2.2. Actual PTBCH weight/volume fractions (w/v) in 0%, 5% and 10% 
PFC-media 
% Oxycyte® (v/v) % PTBCH (w/v) 
% PTBCH (w/v) in tested 
media 
0 60 0 
5 60 3 
10 60 6 
 
 
 
 
 
FIGURE 2.1. From left to right: Oxycyte
®
 product emulsion (LEFT); pure 10% 
FBS supplemented MEM-based cell culture medium (MIDDLE), and such medium 
supplemented with 5% Oxycyte
® 
(RIGHT). 
 
 
 
To quantify the effects of PFCs on the quantity of O2 aqueous solutions can 
dissolve, a series of calibration experiments were completed: emulsions of 0%, 5% and 
10% (v/v) Oxycyte
®
 PFC emulsions in normal cell culture medium were prepared. For 
the remainder of this study, 0%, 5% and 10% Oxycyte
®
 (v/v) in media, will be referred to 
Oxycyte
®
 Pure medium 5% PFC-Medium 
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as “0% PFC-medium” (or “normal medium”), “5% PFC-medium” and “10% PFC-
medium”, respectively. The actual PTBCH weight/volume fractions for these three 
emulsions are shown in Tab. 2.2. 
The dissolved O2 (DO) concentrations of the PFC-media were measured at 37
o
C 
using the single-loop flow circuit shown schematically in Fig. 2.2. As illustrated, 100 mL 
of the target PFC-media from reservoir (Fig. 2.2-b) in 37
 o
C incubator (Fig. 2.2-a) was 
pumped through a 95% O2/5% CO2 (Fig. 2.2-d) pressurized gas exchanger (Fig. 2.2-c), at 
the rate of 4.1 mL/minute using an Ismatec BVK peristaltic pump (Cole-Parmer, Vernon 
Hills, IL) (Fig. 2.2-e). This gas exchanger (Fig. 2.2-b) consists of a Pyrex
®
 500 mL glass 
bottle (Corning, Lowell, MA) with a threaded cap and a pair of press-fit gas inlet and 
outlet on the cap. A 0.5 m long, gas-permeable silicone tubing (inner diameter≈1.6mm) 
(Nalge Nunc, Rochester, NY) was coiled in the bottle. Conventionally used in sterile gas 
exchange, this tubing allows O2 diffusion into the flowing liquid. Gas gauge pressure was 
adjusted at 50 kPa and gas influx is controlled by an air flow meter (Cole-Parmer, Court 
Vernon Hills, IL). Gas flow rate was initially set at 0.1 L/minute until equilibrated. Given 
ideal equilibrium the estimated absolute O2 partial pressure (pO2) inside the Pyrex
®
 glass 
bottle was over 1000 mmHg. The DO value was measured using a polarographic 
AccumetXL60 DO meter (Thermo Fisher Scientific, Waltham, MA) with an electrolytic 
solution-filled, membrane-capped cell. For sampling, 5 mL of media from the bulk flow 
was released every 5 minutes (Fig. 2.2-f) beginning 1 minute after pump flow was 
initiated and read by the probe. The tested sample was returned to the circuit for volume 
maintaining. DO measurements continued until the readings approached steady state. 
2.2.2 Media Viscosity Measurements 
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FIGURE 2.2. Schematic diagram of the flow circuit used to determine the DO 
characteristics of the PFC-medium emulsions: (a) Incubator; (b) PFC emulsion 
reservoir; (c) Gas exchanger; (d) O2 tank; (e) Peristaltic pump; (f) Sampling point by a 
3-way connector. 
 
 
 
The viscosities
**
 of 0%, 5% and 10% PFC-medium at 37
o
C were measured using 
a Cannon-Fenske viscometer (Cannon Instrument, State college, PA). Sample 
temperature was maintained throughout the measurement using a 37
o
C water bath. 
  
                                                        
v. ** Viscosity is a physical property of fluid that measures the resistance to deformation of such 
fluid. 
e 
f b 
c 
a 
95% O2 
5% CO2 
d 
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2.3 Results 
2.3.1 Dissolved O2 Concentration of PFC-medium 
 
 
FIGURE 2.3. Dissolved O2 characteristic curves of pressuring oxygenated PFC-media 
with different fractions of PFC at 37
o
C. #:5%PFC >0%PFC at each data point in 
dashed-line box, p<0.05; ##: 5%PFC>10%PFC at each data point in box, p<0.05. n=3. 
Mean±SE.; 
 
 
 
Before one could quantify whether PFC supplementation increases the functional 
performance of 3D hepatic tissue equivalents, it was first necessary to quantify the effects 
of PFC on the DO concentration of nutrient medium. The results of this are shown in Fig. 
2.3. Of the three PFC concentrations indicated (0, 5, and 10% v/v PFC), 5% PFC-
medium maintained the highest DO level for majority of the experiment’s duration. As 
previous cell culture results indicated 10% PFC started to demonstrate cytotoxicity, 5% 
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PFC-medium will be the concentration to supplement medium in the associated cell 
function study (see CHAPTER 3). Surprisingly, Fig. 2.3 also indicates that the 10% v/v 
PFC fraction experienced a lower DO concentration than the 5% fraction under the same 
O2-pressurizing condition. This could be due to other material properties affected by the 
PFC volumetric fractions. Therefore the viscosities of the 3 PFC emulsions based on 
medium and water were measured and results were graphed in Fig. 2.4. In this figure, 
10% PFC-medium is the most viscous solution of the three, while the viscosity of 5% 
PFC-medium is fairly indistinguishable from that of normal medium (0% PFC). 
 
 
FIGURE 2.4 Viscosities of 0%, 5% and 10% (v/v) PFC-medium and PFC-water at 
37ºC.*: p<0.05. n=3. Mean±SE 
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2.4 Discussion 
The O2 capacities of three PFC-medium concentrations were quantified within 
this study (Fig. 2.3). This is the first time this has been measured for a commercially 
prepared PFC product Oxycyte
®
. A PFC product – Oxygent
®
 – in perfusate at 
concentration 6.4% (v/v) were computationally predicted to increase delivered O2 than 
3.2% PFC supplemented perfusate [52]. Another PFC (species not specified) numeric 
model in hepatic hollow fiber bioreactor predicted that O2 transfer flux in bioreactor 
increases with climbing PFC volume fraction [53]. These simulated results seemingly 
suggest that larger PFC volume fractions necessarily result in higher O2 capacities of the 
overall emulsion. While these models considered the viscosities, their impact on the 
dissolved O2 concentration of the perfusate was overlooked. 
The immiscible PFC disperses as nanodroplets in aqueous medium [43], forming 
a biphasic emulsion system. Thus mathematical relation between its volume fraction and 
the overall viscosity for a dilute emulsion is [54, 55]: 
  
  
 
 
 − √ 
3
 ( 2.1 )  
where    is the effective viscosity of emulsion,    is the viscosity of the continuous 
phase (e.g., aqueous medium), and   is the volume fraction of dispersed phase (e.g., 
PFC). A more complex representation – Taylor’s equation – describes this relation as 
[56]: 
  
  
   (
   
5
2  
     
)  ( 2.2 )  
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where    is the viscosity of dispersed phase (i.e., viscosity of PFC). Both equations 
indicate that PFC-medium viscosity is expected to increase with PFC additions. This 
theory is substantiated by the results of Fig. 2.4. Connecting this to the results of Fig. 2.3-
a suggests that the statistically significant viscosity increase of the 10% (v/v) PFC-
medium, as compared to 5% v/v, interferes with its O2 solubility. This conclusion is 
consistent with work reported for the custom PFC emulsion “Fluroxygen”, where the 
25% volume fractions did not achieve higher O2 solubility than the 15% limit [57]. 
Similar phenomenon was also reported in fermentation process when the viscosity of 
fermenting liquid increases[58, 59]. It was believed the increased viscosity adversely 
slows down water-PFC interfacial O2 exchange rate. This transport impedance is believed 
subsequently curtailing the overall O2 delivery efficiency and O2 solubility in emulsion 
[57]. However, such interfacial O2 exchange rate was regarded not obstructed in previous 
modeling analysis and thus led to totally different conclusions [52, 53]. 
Further investigation of mass transfer in emulsion elaborates why viscosity 
thresholds O2 transfer efficiency. The biphasic mass transfer of a single viscous droplet 
(dispersed phase) moving in continuous-phase liquid was numerically modeled [60]. The 
results showed as the viscosity ratio   /   in Eqn. 2.1&2.2 (specifically             /
           in this study) increases, the overall convective mass (including O2) transfer 
(represented by Sherwood number
††
) decreases 
‡‡
[60]. Such limited O2 convective 
transfer hinders PFC O2 transport efficiency. As a result, more viscous PFC-medium will 
have a lower O2 transfer rate. 
                                                        
vi. †† Sherwood number is the ratio of convective mass transfer coefficient to the diffusive mass 
transfer coefficient.  
vii. ‡‡ Given Reynolds number‡‡ (Re) and Péclet number‡‡ remain constant within the range Re < 
1000, Pe <500, as premises. 
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Another cause for the 5% and 10% PFC-media DO difference in results of Fig. 
2.3 could be from the measuring DO probe itself. From theory appendix of its user 
manual, the DO probe measures pO2 according to the current strength between its gold 
cathode and silver anode. The O2 concentration value was calculated by device program 
based on the assumption that measured solution is totally aqueous. However, this preset 
condition does not apply to the PFC emulsion in this dissertation. 
The composite solubility of PFC emulsions is [61]: 
      𝑖 𝑖          
      𝑖 𝑖   𝑞      ×    % 𝑞            𝑖 𝑖  𝑃𝐹𝐶 ×    %𝑃𝐹𝐶  
( 2.3 )  
and the DO concentration then is calculated as: 
   𝑐  𝑐𝑒     𝑖   𝑝  ×      𝑖 𝑖           ( 2.4 )  
The 5% and 10% PFC-medium emulsion should have different O2 solubility due 
to different PFC volume fractions, which however was preset as the same value that only 
applies to aqueous solution in the Clark type DO probe device. But the pO2 values it 
measured can be used to calculate the actual O2 concentration in PFC-media. The 
Oxycyte
®
 O2 solubility is 0.566 mL O2/(L pure PTBCH∙mmHgO2) at 37ºC [51], while 
the rest part in PFC-medium is assumed as pure water for simplified calculation and its 
O2 solubility at 37 ºC is 0.0337 mL O2/(L water∙mmHgO2)[62]. Through water 
weight/volume fraction (confidential product information) and PTBCH weight/volume 
fraction, the final PTBCH volume fraction in PFC-medium (instead of its weight/volume 
fraction as in Tab. 2.2) can be obtained and the composite O2 solubility of PFC emulsion 
in Eqn. 2.3 is evaluated. Fig. 2.5 shows the recalculated DO values presented in 0% 
(purely aqueous), 5% and 10% PFC-media. This calibration study of this dissertation 
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work thus has clarified different PFC fractions result in emulsion’s different DO 
concentrations. Because previous preliminary cell culture showed the cytotoxicity of 10% 
PFC in medium and its O2 solubility is close to that of 5% PFC-medium (Fig. 2.5), it is 
the 5% PFC-medium that will be applied to following hepatic cell culture (see 
CHAPTER 3). Though generally regarded as not acutely toxic [63, 64], various levels of 
cytotoxicity by different PFCs to non-hepatocytes had been confirmed in the literature 
[43, 65, 66]. The hepatic cytotoxicity of the specific PTBCH that Oxycyte
®
 contains must 
be evaluated in the future if it is to be applied as a supplement in BALs. 
 
 
FIGURE 2.5. (Converted from Fig. 2.3) DO concentrations of O2-pressurized PFC-
media with different fractions of PFC at 37
o
C. *:5%PFC>0%PFC, p<0.05; **: 
10%PFC>0%PFC, p<0.05, #: 10%PFC>5%PFC, p<0.05. n=3, Mean±SE. 
 
CHAPTER 3: USE PERFLUORONCARBONS TO ENHANCE OXYGEN DEVLIERY 
IN 3D THICK HEPATIC TISSUE EQUIVALENT 
3.1 Introduction 
Incorporating PFCs within the perfusate of BALs is expected to benefit its O2 
delivery and elevate functionality. Yet to date this has not been investigated in thick 3D 
hepatic tissue equivalents study, nor has it been presented for the commercially prepared 
PFC emulsion Oxycyte
®
 (Oxygen Biotherapeutics, Durham, NC) characterized in 
CHAPTER 2. “Thick 3D hepatic tissue equivalent” here refers to hepatic culture that has 
significant larger size or dimension than regular multi-well plate culture, such that O2 
delivery to its cellular space will be challenged. There are many hepatic cell candidates 
for BALs [4, 32, 67, 68] and which kind of cells are used for the Oxycyte
® 
efficacy 
evaluation must be determined. The HepG2/C3A cell line subcloned from its parental 
HepG2 hepatoblastoma cell line was selected, because it retains many human primary 
hepatocytes (HPH) phenotypes. These phenotypes include: high albumin and low α-
fetoprotein secretion, strong glucose metabolism, urea production (although not due to 
removal of ammonia[69]), and cytochrome P450 activity [70, 71]. With these key 
functionalities and its proliferative ability, the C3A cell line has been used in clinical 
trials since the 1990s [72, 73] and includes being used in the ELAD
®
 BAL(Vital 
Therapies Inc., San Diego, CA) [11]. Thus, in this chapter, the effects of PFC-
supplemented medium on HepG2/C3A cells function and viability were evaluated for 
thick 3D hepatic tissue equivalent under static and dynamic flow conditions. 
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3.2 Materials and Methods 
3.2.1 Cell Culture 
 
 
FIGURE 3.1. Proliferating HepG2/C3A cells monolayer cultured in a protein-coated T75 
cell culture flask.  
 
 
 
 The human hepatoblastoma cell line HepG2/C3A from American Type Culture 
Collection (ATCC #CRL-10741, Manassas, VA) was used. In the current work, C3A 
cells were cultured in T-75 flasks (Cellstar, Greiner Bio-One, Monroe, NC) and 
incubated with humidified, air-balanced 5% CO2 at 37ºC (Fig. 3.1). The C3A full growth 
medium, based on Eagle’s Minimum Essential Medium (MEM) (Mediatech, Manassas, 
VA), was supplemented with 0.11 g/L (1mM) sodium pyruvate (Sigma-Aldrich, St. Louis, 
MO), 1.5 g/L sodium bicarbonate (Sigma-Aldrich, St. Louis, MO), 10% v/v Fetal Bovine 
Serum (FBS) (Hyclone, Logan, UT) and 1%  v/v antibiotic/antimycotic solution (10,000 
Unit penicillin G, 10,000μg streptomycin and 25 μg/mL amphotericin B, JR Scientific, 
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Woodland, CA). Oxycyte
®
 was supplemented to this full growth medium at 5% for 
following PFC-treatment. The culture medium of each T-75 was changed every other day, 
as well as 24 hours prior to subculture (i.e., passaging). Once 90% confluency was 
attained, cells were trypsinized using 0.25% Trypsin-EDTA solution (Sigma-Aldrich, St. 
Louis, MO) and centrifuged at 800 rpm (~130g) for 5minutes. Cells with passage number 
of no more than 7 were used in this study.  After aspiration, cells were further trypsinized 
with 5 mL of the same Trypsin-EDTA solution then incubated for 25 minutes to facilitate 
cell monolayer detachment and cell aggregate dissociation. 
3.2.2 Extracellular Matrix (ECM) Preparation 
3.2.2.1 Collagen gel as ECM 
Collagen gels have been extensively used as the ECM for in vitro 2D hepatic 
cultivation [74-76] in which primary hepatocytes polarize themselves and demonstrate 
phenotypes as in vivo. To establish a reliable function control to calibrate effects of the 
Oxycyte
® 
PFC, PureCol
®
 Type I collagen purified from bovine source (Advanced 
BioMatrix, San Diego, CA) as ECM was used in 2D double gel (sandwich) cultures. Its 
collagen density was originally ~3 mg/mL yet diluted down to 1.1 mg/mL using 0.1 M 
NaOH solution, 10× Minimum Essential Medium (MEM) and deionized water for this 
work. 
3.2.2.2 Gelatin sponge as ECM 
Since goal of this work is to clarify the effects of PFCs in improving O2 delivery 
to thick 3D tissue equivalents under flow conditions, it was necessary to establish an 
ECM environment amenable to cell attachment and able to withstand aqueous flow. 
Unfortunately the low permeability [77] and weak mechanical properties [78] of collagen 
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impaired its reliable use as the 3D ECM for thick tissue equivalents. Since Gelfoam
®
 
gelatin sponge (Pharmacia & Upjohn, New York, NY) had demonstrated effectiveness in 
supporting mammalian cells [79-82] and exhibited adequate pore sizes (30-700 μm [80]) 
for transport [83], it was chosen as the ECM substrate for the 3D tissue equivalent design 
of this study. To prepare for culture, the Gelfoam
®
 sponge with vendor thickness of 1 cm 
was first cut into 1×1×1 cm cubes (for the static flow study in multi-well plate) and 3.5 
cm diameter discs (for the dynamic flow study). The prepared sponge scaffolds were then 
sterilely pressed in Redi-Pak
® 
straight wall glass jars (VWR, West Chester, PA) to 
remove air from the sponge scaffolds. The sponge scaffolds were then transferred into 
standard 12-well plates (cube) or 6-well plates (disc). Each well was added 2 mL (cube) 
or 6 mL (disc) of 1× Hank’s Buffered Salt Solution (HBSS). After 25 minutes, HBSS 
was aspirated and the rinsing cycle was repeated. Following thorough aspiration, 2 mL 
(cube) or 5mL (disc) of the C3A full growth medium (or PFC-medium) was then added 
into each well, and the 3D gelatin ECM was incubated for another 1 hour prior to cell 
seeding. 
3.2.3 Cell Culture Preparation 
3.2.3.1 Static Cultures 
For the static flow culture study, collagen gel and gelatin sponge were both 
utilized, where cells sandwiched between layers of collagen gel served as function 
control. For the sandwich cultures, each well of a standard 12-well plate (Greiner Bio-
One, Monroe, NC) was coated with 0.34 mL collagen and incubated 2 hours for fully 
gelation. After viability was confirmed by Trypan Blue (Sigma-Aldrich, St. Louis, MO) 
exclusion assay following trypsinization, 1×10
5
 viable C3A cells were plated into each 
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collagen-coated well and were gently shaken to spread evenly. After 2 hours incubation 
for cell anchorage, supernatant of each well was aspirated and 0.34 mL same collagen 
was placed on top of cells. After this top layer fully gelled in 4 hours incubation, 2 mL 
cell culture medium (normal full growth medium or 5% PFC-medium) was added into 
each well. For the gelatin sponge cultures, 1×10
5
 viable C3A cells were inoculated into 
each prepared 1×1×1 cm sponge cube which afterwards were added to standard 12-well 
plate 1 hour later and 2 mL of culture medium (normal medium or 5% PFC-medium) was 
added to each well. Both static sandwich culture and gelatin sponge culture were 
maintained for 10 days at 37°C in 95% air/5% CO2, where their culture media were 
replaced every 48 hours (i.e., day 2, 4, 6, 8, 10). 
3.2.3.2 Dynamic Cultures 
Culture preparation for dynamic study is very similar to static culture excepted 
that each sponge disc was inoculated 5×10
5
 viable C3A cells and there were multiple 
pipetting-inoculations to achieve even cell distribution. Cell leakage was examined to 
confirm inoculation success, by microscopically evaluating the remnant medium left by 
displaced sponge. Cell-loaded sponge discs were incubated at 37°C in 5% CO2/95% air 
for 24 hours prior to use in the custom flow device, for stabilizing cell attachment. 
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3.2.4 Dynamic Flow Culture Conditions 
 
 
FIGURE 3.2. Schematic diagram of the dynamic flow device (II) and its static flow 
culture as control (I): (a) Incubator; (b) Gas exchanger; (c) O2 tank; (d) Peristaltic pump; 
(e) Flow device and its static control device, with cell loaded sponge discs; (f) Stainless 
steel mesh; (g) Sterile venting filter; (h)Teflon
®
 filled cone bottom; (i) Double stacked 
sponge discs; (j) Supporting sectioned syringe barrel. The open downward arrow in (II) 
indicates flow direction in the device. 
 
 
 
The custom flow device designed for this study is schematically shown in Fig. 3.2. 
Its main part consists of a 50 mL polypropylene tube (Greiner Bio-One, Monroe, NC) 
able to accommodate two stacked 3.5 cm-diameter sponge discs (hatched region in Fig. 
3.2). The stacked sponge culture in flow device (Fig. 3.2-i) was sandwiched between 2 
trimmed stainless steel #316 meshes for immobilization against buoyant force (Fig. 3.2-f) 
(Small Parts, Miramar, FL). Since flow through the base of the stacked discs is required, 
the bottom mesh rests on a cylindrical shell platform (Fig. 3.2-j). It was sectioned from a 
30 mL polypropylene syringe barrel (BD Science, Franklin Lakes, NJ,) and effectively 
suspended the stacked discs ~25mm high from the flow device outlet meanwhile 
(I) (II) 
95% O2 
5% CO2 
d 
b 
c 
a 
g 
f 
i 
h 
j 
e 
Disc B 
Disc A 
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allowing flow though. The use of 2 stacked cell-loaded sponges (Fig. 3.2-i) established 
the thick culture thickness (~ 1.2 cm) required for clarifying PFC’s effects on cell 
viability along the Z-axis depth through this 3D culture. Furthermore, it did not interfere 
with the perfusion of the medium through the 3D culture volume. The priming volume 
for the flow device was 20 mL. The medium inflow to the device was oxygenated with 
95% O2/5% CO2 via the same gas exchanger (Fig. 3.2-b) as in Fig. 2.2-c (CHAPTER 2). 
To establish a suitable control for the flow device, a complementary system was 
engineered (shown schematically in Fig. 3.2-I) that differed from the flow system in a 
single feature – it did not have media flow. This static tube thus allows only 
unidirectional passive diffusion to dominate O2 transport to the volume of the cellular 
space. Main difference of such diffusion pattern from static flow’s sponge cube culture is 
that for sponge cube the diffusion occurred on its entire sides and top as there were gaps 
between culture and wall (see Fig. 5.4), while in this static tube medium can only directly 
access top of sponge discs. 
3.2.4.1 The Dynamic Flow Experiment 
As previously mentioned, the cell-loaded sponge discs were added to the dynamic 
flow device (Fig.3.2-II), and its static control (Fig. 3.2-I) 24 hours after preparation. After 
20 mL medium (normal or PFC-supplemented) was added to the culture-loaded dynamic 
flow device, its pump started at the rate of 0.25 mL/minute. The static control (Fig. 3.2-I) 
was added 20 mL medium (normal or PFC-supplemented) while dynamic flow device 
began operating. Both cultures in Fig. 3.2-I and Fig.3.2-II were maintained for 48 hours 
from flow initiation. During the whole culture period, color of phenol red-contained 
medium in dynamic flow device and static control was monitored and stable color 
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through the culture indicating pH ~7.4 was observed. At the end, the viability, albumin 
secretion, glucose reduction, CYP450 activity (EROD) and propagated population of the 
cells in each sponge disc were assessed. 
3.2.5 Function and Metabolic Activity Studies 
3.2.5.1 Albumin Secretion 
One of the key HPH functions retained by C3A cells is albumin secretion. The 
albumin concentrations of day 2, 4, 6, 8, 10 (static study) or end of culture (dynamic 
study) were measured using a standard enzyme-linked immunosorbent assay (ELISA) as 
per vendor’s protocol (Human Albumin ELISA Quantitation Kit, Bethyl Laboratories, 
Montgomery, TX). Measurements were quantified using a Synergy HT microplate reader 
(Bio-Tek, Winooski, VT) read absorbance at 490 nm wavelength. The total secreted 
albumin values were calibrated against standard curves.  
3.2.5.2 Glucose reduction 
Energy of metabolism mainly comes from the glucose breakdown (glycolysis). To 
monitor the energy consumption of the cultured cells, the glucose concentrations of the 
spent culture medium (static study: day 2, 4, 6, 8, 10; dynamic study: end of culture) were 
read at absorbance of 630 nm using the QuantiChrom Glucose Assay Kit (BioAssay 
Systems, Hayward, CA). The glucose reduction was calculated as the quantitative 
difference between the glucose level of spent sample medium and that of the cell-free 
stock medium. The total glucose reduction was calibrated against standard curves. 
3.2.5.3 Cytochrome P450 (CYP450) activity 
In human liver, cytochrome P450 (CYP450) is a large family of isoenzymes that 
play key roles in phase I drug metabolism. Among such enzymes, CYP1A1 and CYP1A2 
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catalyze the ehoxyresorufin o-deethylase (EROD) and their activities are typically tested 
through EROD assay where ethoxyresorufin (ER) (Molecular Probes, Eugene, OR) is the 
substrate [84-86]. In this study, the EROD assay applies to the ability of C3A cells to 
retain CYP1A2 function.[71] C3A cell-loaded cultures were dosed with 2µM 3-
Methylcholanthrene (3-MC) (Sigma-Aldrich, St. Louis, MO) medium for 48 hours prior 
to the EROD evaluation [71]. 
The product of the EROD assay is resorufin and its production rate – the level of 
resorufin produced over a specified time period – is an indicator of CYP450 activity. 
Since this assay requires inducing medium containing the drug 3-MC, it cannot run 
parallel with albumin and glucose assays. In the static study the EROD activities of 
independent C3A cell groups were tested on day 3, 6 and 9. In the dynamic flow study, 
cell culture for EROD assay was tested at end of culture. For the static flow study, to 
remove residual 3-MC medium at the endpoint of dosing each culture was rinsed using 3 
mL HBSS for 30 minutes incubation. Later 2 mL 5 µM ER in 50 mM HEPES buffer 
solution was added followed by 3 hours incubation at 37°C. For the dynamic flow study, 
3-MC medium was drained at the end of 48 hours, when perfusion flow was stopped. 
Each sponge disc was relocated from flow device into a new standard 6-well plate. Each 
disc was then added 6 mL HBSS and the sponge discs were incubated at 37°C for 30 
minutes to remove excess 3-MC medium, then the excessive supernatant aspirated. 
Subsequently, 5 mL of 10 µM ER in phenol red-free medium (Mediatech, Manassas, 
VA) was added to each well and incubated for 6 hours. 
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3.2.5.4 Resazurin Metabolism Assay 
Resazurin (Sigma-Aldrich, St. Louis, MO) is the main functioning component of 
the commercial dye alamarBlue
® 
[87] which is widely used in cell viability and 
cytotoxicity determinations [87-92]. In this study, resazurin (Sigma-Aldrich, St. Louis, 
MO) was used to determine the metabolically active population (MAP) of the cell loaded 
sponge during continuous proliferation, and such population results were used in 
normalization of function results. Resazurin was prepared as 3 mM stock solution by 
being dissolved in HBSS. Such stock solution was then diluted in phenol red-free culture 
medium (Mediatech, Manassas, VA) to achieve a 10% (v/v) resazurin-medium solution.  
In static flow study, 2 mL of 10% resazurin-medium was added to each sandwich 
culture/sponge cube within 12-well plates and incubated for 2 hours. For dynamic flow 
study, after perfusion ended and discs being relocated to the new 6-well plate, 5 mL 10% 
resazurin-medium was added to each 3.5 cm-diameter sponge disc and incubated for 2 
hours. Each well was sampled 3 aliquots of 100 µL solution from each well were 
transferred to a 96-well plate (Nunc, Rochester, NY). Standard resorufin solution 
(concentrations ranging 0-20 μM) was then pipetted into the same plate, and the 
fluorescence signal of each well was read by Synergy HT microplate reader (Bio-Tek, 
Winooski, VT) at the excitation/emission of 530/590 nm. Resorufin production was 
determined from standard curves. Following the completion of the metabolic assay, each 
sponge disc was exposed to 2 cycles of a 30 minutes HBSS rinse, to minimize remaining 
fluorescent noise and prepare for fluorescent viability study. 
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3.2.6 Evaluation of Cell Viability 
It was important to quantify whether cell viability varies with Z-position along the 
thick tissue equivalent at the conclusion of experiments. In this study, C3A cell viability 
was determined through using nuclei fluorescence dyes: 1 µg/mL concentration of 
Hoechst 33342 and 1 µM Ethidium Homodimer-1 (EthD-1) (Molecular Probes, Eugene, 
OR). Since EthD-1 is sensitive to serum, it was necessary to first remove the FBS in the 
medium before viability could be assessed. This was achieved by placing each cell-
loaded sponge disc tissue equivalent in the well of a 6-well plate, followed by twice 
soaking in 1×HBSS, where each soak was of 20 minutes duration. To ensure that FBS 
was removed from the sponge interstitial space, each sponge disc in dynamic study was 
rinsed by 6 mL HBSS. After aspiration of HBSS supernatant, the hybrid Hoechst-EthD 
HBSS was added to each sponge tissue equivalent and incubated at 37°C for 1 hour. 
After aspiration, the cell-loaded sponge discs were fixed by equilibrating each cell loaded 
cubic and disc sponge with 5 mL of 10% formalin (VWR, West Chester, PA) to prevent 
Hoechst efflux by transport protein [93-96]. The excess formalin was then aspirated and 
HBSS was added for another 30 minutes incubation. After the last aspiration the fixed 
tissue equivalents were stored at -80
o
C until the microtome work was initiated. 
Since the 3D sponge disc cultures were too thick and opaque to be viewed readily 
via confocal microscopy, it was necessary to slice each fixed tissue equivalent using a 
HM550 Microtome cryostat (Microm, Walldorf, Germany) at 3 designated positions (Fig. 
3.3, I, II and III). Prior to slicing, the frozen and fixed tissue equivalent sample was 
chilled in the -20
o
C chamber of the cryostat. It was then thoroughly coated with Tissue-
Tek
®
 Optimal Cutting Temperature compound (Sakura Finetek, Torrance, CA), then 
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sliced to 100 μm thick segments, thickness of which is to ensure its full integrity (thick 
black lines in Fig. 3.3-a represent such layers). Each layer was then positioned on a 
75×50×1 mm microscope glass slide (Fisher Scientific, Pittsburgh, PA). Since the total  
 
 
FIGURE 3.3. Schematic demonstrating: (a) The slice thicknesses used in the cell viability 
evaluation procedure for each 3D sponge disc (A and B); (b) the positioning of cell-
loaded sponges A and B, and the positions of their cryostat slices for confocal imaging 
(totally 6 positions, while A-I, II&III are different cryostat slice of one sponge disc A, 
same as B-I, II&III), within the thick 3D tissue construct of the dynamic flow condition 
in this study. 
 
 
 
height of each frozen sponge disc was ~6000 μm, it was sliced at 900 μm, 2900 μm and 
4900 μm away from top surface (Fig. 3.3). The viability of the prepared tissue equivalent 
slices was then quantified using an Olympus IX70 laser scanning confocal microscope, 
and documented using FluoView 5.0 (Olympus America, Center Valley, PA). Each 
sample slice was imaged 5 random fields. The results were averaged to quantify the 
overall viability of one single slice. Because Hoechst 33342 stains all cell nuclei, while 
EthD-1 stains dead cells, the number of viable cells was obtained by subtracting the dead 
cells (EthD-1 marked) from the total cells (Hoechst marked). 
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3.2.7 Plot and Statistical Analysis 
Plotting of the O2 concentration, viscosity, population-normalized function results 
(Fig. 3.2-3.6) and the statistical analysis were completed using OriginPro (OriginLab, 
Northampton, MA). One-way Analysis of Variance (ANOVA) is used to determine 
significance of differences between mean values. Unless otherwise specified, p<0.05 is 
regarded as statistically significant. For the PFC O2 concentration calibration, 3 
independent samples were analyzed (n=3), such that each 100ml sample was only used 
once in the calibration.  In evaluating the viscosity of each condition (e.g., PFC media, 
normal media) 3 samples (n=3) were used, where each sample was measured three times 
via the viscometer. For the function studies, experiments were conducted on triplicate 
separate samples, where each experiment was independently repeated three times. 
3.3 Results 
3.3.1 Effects of PFC on Liver Function 
Since adding 5% v/v PFC to normal medium significantly enriched its O2 
concentration (CHAPTER 2), it was necessary to ensure that this addition would not 
negatively affect the cells functionalities. In all figures and discussions beyond this point, 
5% Oxycyte
®
 PFC-medium will be referred to as “PFC-medium”. C3A cells were then 
cultured in the presence of PFC-medium under traditional static conditions, which 
include two ECMs: collagen double gel and gelatin sponge 3D scaffold to evaluate PFC’s 
effect. 
3.3.1.1 Static collagen sandwich culture 
Functional results in collagen sandwich culture were recorded into Fig. 3.4-I, 
including albumin secretion, glucose reduction, and EROD activity. The normalized 
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results via resazurin assay-determined cell population are presented, to elucidate PFC’s 
effect on such a dynamically proliferating cell line. While in sandwich culture both 
normal and PFC-medium treated cells had a decreasing trend of albumin secretion per 
cell (Fig. 3.4-Ia), there was no statistical difference between these two groups through the 
cultured period. Meanwhile their glucose reduction results through the same period 
entailed that through 10 days culture, both normal and PFC-medium treated cell group 
had stable and same level of energy consumption per cell (Fig. 3.4-Ib). For CYP450 
assay, only normal medium-treated C3A cell had an increasing EROD activity from day 
3 to day 9 (Fig. 3.4-Ic), and on day 6 normal medium-treated group had higher resorufin 
production rate than PFC-medium treated group per cell (Fig. 3.4-Ic). 
3.3.1.2 Static gelatin sponge 3D culture 
Fig. 3.4-II illustrates PFC’s effects on the same three functionalities of C3A cells 
in sponge culture: albumin, glucose reduction and EROD activity as compared to that of 
normal medium Cells cultured in static PFC-medium performed equivalently to those 
cultured in normal medium except day 6 and day 8 with respect to albumin secretion (Fig. 
3.4-IIa). Their glucose reductions (Fig. 3.4-IIb) throughout the 10 day period were also 
not significantly different through the 10 day culture period. The effects of PFC-medium 
having more O2 available to the sponge-cultured cells revealed its most pronounced 
effects on CYP450 activity – where cells exposed to PFC-medium yielded significantly 
higher EROD activity than cells in normal medium by day 6 of the culture (Fig. 3.4-IIc), 
but this effect was not seen on day 9.  
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 I II 
a 
  
b 
  
c 
  
FIGURE 3.4. Population-normalized albumin (row a), glucose reduction (b) and EROD 
activity (c) of initially 1×10
5 
C3A cells cultured in collagen gel sandwich (column I) and 
sponge cube (II) in static multi-well plate. n=9.*: p<0.05. Mean±SE. 
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3.3.1.3 Dynamic gelatin sponge 3D culture 
Fig. 3.6 presents the normalized results of PFC-medium exposure on C3A cells 
under dynamic flow and static conditions. The functional performance is compared to 
that in normal medium. As illustrated in Fig. 3.6-a, under dynamic flow conditions C3A 
cells cultured in PFC-medium secrete albumin at equal level of cells in normal medium, 
while consuming less glucose (Fig. 3.6-b). The exposure to PFC-medium seemed not to 
directly enhance single cell’s ability of accomplishing EROD activity, but to encourage 
the cell population growth under flow condition though not statistically significant (Fig. 
3.5-a). As shown in Fig. 3.5-b, the MAP of C3A cells in flow device with 3-MC dosing 
proliferated from 1×10
6
 to ~4×10
6
 after 48 hours. Such a change is significantly different 
from its normal medium-treated counterpart (Fig. 3.5-b). 
 
a 
 
b 
 
FIGURE 3.5 Metabolically active populations (MAPs) of C3A cells at endpoint of 
albumin and glucose reduction assays (a) and EROD activity assay (b) (population used 
to obtain normalized results in FIGURE 3.6). n=3.*: p<0.05. Mean±SE 
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FIGURE 3.6 Population-normalized albumin (a), glucose reduction (b) and EROD 
activity (c) of initially 5×10
5 
C3A cells cultured in dynamic flow tube device and static 
tube as control. n=3.*: p<0.05. Mean±SE 
 
 
 
3.3.2 Cell Viability through Z-axis of Thick 3D Tissue Equivalents 
It is necessary for O2 to be transported effectively throughout culturing thick 3D 
tissue equivalents. Since the normal function of hepatic cells, including C3A cells, are 
highly O2 dependent, it was necessary to quantify the viability of the cells within the cell-
loaded sponge cultures of the current work. The viability results for different layers of the 
thick tissue constructs are shown in Tab. 3.1. The position of each layer along the z-axis 
is shown in Fig. 3.3. The results indicate that for normal and PFC-medium conditions, 
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cell viability was very high (> 98%) throughout the duration of the culture for both 
normal and PFC-medium treated cells in flow device. 
 
TABLE 3.1: Cell viability results for 3 incremental positions along the Z-axis of the 
3D tissue equivalents 48 hours after flow system start (i.e. 72 hours after cell 
seeding). No statistical difference detected. Results listed as Mean ± SEM. n=6. 
 Conditions
§§
 
Z Positions NM-S NM-D PFC-S PFC-D 
A-I 98.63±0.69% 99.11±0.64% 99.57±0.37% 99.51±0.33% 
B-I 99.67±0.71% 97.64±1.18% 98.89±1.04% 100±0% 
B-III 98.67±0.82% 100±0% 99.84±0.15% 99.86±0.14% 
 
 
 
 
3.4 Discussion 
3.4.1 PFC’s Effects on Cell Functionalities and Viabilities 
A successful method for enhancing O2 transport through 3D tissue spaces of BAL 
and other applications must minimally establish an environment that supports viable 
functioning cells. The results of the current study demonstrate that together with the 
custom designed flow device and Oxycyte
®
 PFC, this was successfully achieved for C3A 
cells-seeded 3D thick tissue constructs. The work shows that the use of 5% v/v PFC-
medium is slightly effective in static culture, and more effectively improving C3A cells 
functional performance under perfusive flow condition. 
 
                                                        
viii. §§ Condition abbreviations: NM = Normal Medium, PFC = PFC-medium, S = Static, D = 
Dynamic. 
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FIGURE 3.7 In a standard 12-well plate (LEFT), normal medium treated, clear collagen 
gel (white line marked) and 5% PFC-medium treated collagen gel for 3 days (black line 
marked), where a closer view shows that PFC sediment gives collagen a cloudy look 
(RIGHT). 
 
 
 
The benefits of enhanced O2 availability on the functional performance of primary 
hepatocytes have been previously reported [24, 30, 34, 38, 97, 98]. Yet the 
responsiveness to enhanced O2 conditions of human hepatic cell line albumin synthesis 
appears to be method and cell source dependent. The PFC-treated porcine primary 
hepatocytes (PPHs) in their perfusion system had equivalent glycolytic activity as normal 
medium treated control (ambient condition) and are even less glycolytic at 5% O2 [46]. In 
a bovine erythrocyte-conditioned hollow fiber bioreactor, over 7 days were taken to 
demonstrate effect of increased O2 on the inoculated C3A cells’ albumin production [99, 
100]. Contrastingly, when a C3A loaded bioreactor perfusate was supplemented by a 
Russian commercial PFC Perftoran
® ***
 (Pushchino, Moscow, Russia), the initial 
population-normalized albumin production increased significantly above its control [35]. 
However, the results of each study aforementioned were not quantified by immediate cell 
                                                        
ix. ***Perftoran® is a blend of perfluorodecalin (C10F18) and perfluoromethylcyclohexylpiperidine 
(C12F23N). 
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population (instead of “initial population” as population beginning of cultivation). For 
example, it was not clear in the Perftoran
®
 PFC study[35] whether the improved albumin 
production was achieved through enhanced protein synthesis per cell or more populated 
cells, or both under increased O2 condition. In another PFC-free 3D perfusion conditioned 
study, the albumin secretion of C3A cells in alginate-based 3D culture (scaffold pore size 
at 65-85 µm, flow rates at 60 mL/min or 100 mL/min) was also normalized via 
population of day 0 (literally “initial population”), not the actual population at the assay 
moment.[18] In order to portray more precise normalized function results, the resazurin 
assay is introduced for obtaining the key number of MAP. 
Subcloned from its parental cell line HepG2, available literature data of C3A cell 
line are more limited than the vastly investigated HepG2. Borrowing intelligence of 
HepG2 cell line could assist the analysis for C3A cells – after all, these two are 
genetically related [70]. The albumin regulations of HepG2 cells and RPH using 
hepatocytes growth factor are different [101]. In addition, hypoxia condition does not 
inhibit the HepG2 albumin gene sequence expression.[102] These indicate that albumin 
expressions of HepG2 cells may be notably different than that of primary hepatocytes. 
Such a difference may contribute to the fact that HepG2 cells secreted more net albumin 
than RPH 24 hours after inoculated in bioreactor [103]. Moreover, due to altered CYP450 
expression, HepG2 cells are also known to have weaker EROD activity as compared to 
RPH [86] and HPH [104, 105]. This also elucidate why the EROD levels achieved by 
C3A cell line here are lower than that previous RPH-based study using normal medium 
[106]. It should be concluded that the C3A cells response to O2 exposure can only be 
poorly predicted from primary hepatocytes behavior. 
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In static collagen sandwich culture, PFC’s effect to C3A cells was not obvious 
(Fig. 3.4-Ia, Ib & Ic). The PFC-medium conditioning did not create a difference from the 
normal medium at both albumin secretion and glucose consumption. Rather, in EROD 
activity study normal medium treated cells had even higher EROD activity than PFC-
medium treated cells on day 6. This could be attributed to the PFC deposition on collagen 
gel. Heavier than water, if statically placed PFC droplets in PFC-medium emulsion sink 
to the bottom and precipitate. Medium refreshing only removes supernatant yet the PFC 
deposition stays (Fig. 3.7), leaving an oil-like film hindering other nutrients (glucose, 
growth hormone, amino acids etc.) transport from medium through collagen. This side 
effect may contradict PFC’s O2 benefit to cell functioning in following cultivation. 
On day 6 of static gelatin sponge culture PFC-conditioned CYP450 activity per 
cell is significantly higher but this did not recur on day 9 (Fig. 3.4-IIc). A reasonable 
answer is that expression of EROD enzyme had remarkably decreased before day 9 due 
to its continuously degrading mRNA, probably as a result of cell line’s altered liver 
enriched transcriptional factors (LETFs) [86, 107]. While Fig. 3.6-a shows that under 
flow condition, albumin productions of cells treated by normal and PFC-medium are 
equal, the glucose consumption of the PFC-medium treated (Fig. 3.6-b) is less. Together, 
this lower cell glucose consumption suggests that under PFC and flow condition, higher 
energy per glucose molecule was released such that each cell cost less glucose to secrete 
equivalent level of albumin, or increased gluconeogenesis. Fig. 3.5-b indicates that when 
the 3-MC perfusate in C3A-loaded flow system was supplemented by PFC, more 
metabolically active C3A cells proliferated, with each cell still able to maintain the same 
level of EROD activity as control (Fig. 3.6-c). 
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3.4.2 Conclusions 
To summarize, this study presents the effects of adding PFCs to normal medium 
on the functional performance output of thick 3D hepatic tissue constructs, under flow 
and static culture conditions. The results also demonstrate that the increased O2 
concentration of PFC-medium significantly reduces the glucose consumption during 
albumin secretion per cell and stimulates cell growth under flow conditions. As such the 
results of this work can be applied to the design and support of future BALs in which the 
support of sizable 3D tissue spaces is critical. As a conclusion, by delivering more O2 
into the 3D gelatin sponge ECM interstitial space, the PTBCH-based PFC-medium 
ensures high viability and improves key functionalities of the human hepatoma cell line 
HepG2/C3A into cellular spaces. 
CHAPTER 4: PREDICTING OXYGEN TRANSPORT IN A NOVEL HEPATIC 
BIOREACTOR NUMERICALLY FOR ITS MELIORATION 
4.1 Introduction 
A novel prototype of Four-Quadrant Bioreactor (4QB) was designed and 
fabricated for hepatic support [106].
 
Such study verified that the 4QB created a unique 
dynamic flow environment for the rat primary hepatocytes (RPHs) it housed and enabled 
RPHs to achieve improved functional performance. It also revealed that as RPHs 
population increased to 32 million per quadrant, oxygen (O2) deficient regions appeared 
in the cellular spaces. This implies that the total functional output of the 4QB could be 
even further elevated along with O2 enhancement. Considering numerical methods based 
upon computational fluid dynamics (CFD) theory have been widely applied to modeling 
flow in bioreactor [29, 53, 108, 109], such computation has the potential to resolve the O2 
delivery issue in 4QB at high cost-efficiency. In this study, prediction of O2 transport 
within the 4QB was established by a simplified 3D model capable of representing 
otherwise complicated real multiphase flow. A number of variables (e.g., flow rate, cell 
populations, the spatial flow pattern dictated by cartridge arrangement etc.) presumably 
influence the cellular O2 accessibility in 4QB jointly. Computational results have 
successfully shown that of these variables, local O2 diffusivity in extracellular space is a 
factor as important as the flow rate, while increasing the latter yields higher shear stress. 
The model answers the question that in order to meliorate the local O2 diffusivity for 
amplifying the overall 4QB cellular O2 level without altering original medium formula, 
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ECM material selection is the key. This model also suggests that in CHAPTER 2, prior to 
PFC usage the gelatin sponge 3D scaffold may have already establish the 1
st
 step toward 
O2 transport enhancement. 
4.2 Theory 
The total O2 mass flow within a bioreactor universally obeys the law of mass 
conservation: (adapted from [110]) 
  
  
   (  ⃗⃗)     ( 4.1 )  
where (  )  is the divergence operator,  ⃗⃗  is velocity vector,    is the mass source 
(positive if mass is generated, negative if mass is consumed). Particularly, if flow 
involves both gas and liquid, the mass conservation governing equation for the dual phase 
flow is: 
 (    )
  
   (     ⃗⃗)     ( 4.2 )  
where    is volume fraction of liquid,    is density of liquid. In a computational grid, 
volume fraction of gas is calculated as:     −   . Similarly, the momentum of the O2-
contained flow of 4QB also conserves as: (adapted from [110]) 
 
  
(  ⃗⃗)    (  ⃗⃗ ⃗⃗)  −      (  ⃗⃗  ( ⃗⃗) )   ⃗    ( 4.3 )  
where   is the gradient operator,   ⃗⃗ ⃗⃗ is the momentum of interested mass flow (i.e. ̇  ⃗⃗ 
where ̇  is mass flow rate),   in viscous term  (  ⃗⃗  ( ⃗⃗) ) is the dynamic viscosity,  ⃗ 
is the body force term (such a gravitational force   ⃗), and   is momentum source term. 
The entire device during previous experiments was placed in a 37ºC incubator such that 
the device temperature was equilibrated at 37ºC. Thus there was no net heat exchange in 
the system and energy-affected mass transport is minimal in simulation. 
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4.2.1 Momentum Loss in Porous Structure 
PureCol
®
 collagen (Advanced BioMatrix, San Diego, CA) had been applied in 
4QB as the extracellular matrix (ECM). Collagen is a typical porous biomaterial 
constructed via polymeric crosslinking generating interconnected protein fibers. It 
possesses variously sized pores in 3D space which allow fluid to pass. Meanwhile it also 
hinders fluid free convection and causes the momentum loss. In theory, this momentum 
loss can be characterized by making momentum source term on right side of Eqn (4.3) as 
[111]: 
   −(∑      
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where (∑       
 
   ) is viscous loss and (∑    
 
 
 
    | |  ) is inertial loss (significant in 
turbulence), 𝑖  and   are indices from 1 to 3,     and     are the i-jth components of 
coefficient matrix   and  . | | is velocity magnitude. 
When material structure can be simplified into one-dimensional (1D, e.g. a thin 
membrane), the momentum loss in such 1D homogenous porous medium is presented 
as:(adapted from [111]) 
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where   is the permeability in Darcy’s law, i.e. the ability porous material allows fluid to 
permeate [112, 113]: 
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where   is volumetric flow rate,   is cross-sectional area fluid permeates and ratio of   
and   yields the superficial velocity  ̅ ,    is the length that fluid diffuses driven by 
differential pressure   . 
4.2.2 O2 Effective Diffusivity in Porous Material 
4.2.2.1 Porous material geometry and permeability 
Not only for collagen but in general, porous materials impede the fluid 
transporting through them and thus hinder the motion of soluble substances in fluid. 
Therefore the local mass diffusivities in porous material are lowered than in free liquid. 
The magnitude of momentum loss by such a hindrance is ruled by permeability of 
material itself, which relies greatly on porous characteristics. Two theories surveyed from 
literature mathematically answer how the permeability is affected by porous material 
geometric features: the first is deduced from fiber diameter as key parameter [114], and 
the other is based upon pore size [115]. 
Considering collagen in the 4QB cell culture, in “fiber diameter theory”, as the flow is 
assumed to pass through an 3D array of fibers, the scalar collagen permeability    is 
calculated from collagen fiber volume fraction and fiber diameter [114]: 
    
  [
 
2  
(−    −        (   )  )] ( 4.7 )  
where   is the averaged collagen fiber diameter and   is the collagen fiber volume 
fraction (     ),  (   )   is the error margin. For maximizing computational 
accuracy in our 4QB collagen space, the representative value of fiber diameter   must be 
determined experimentally, or from literature. 
In “pore size theory”, the scalar collagen permeability    is calculated from 
collagen fiber volume fraction, collagen geometric factor, and pore size [115-117]: 
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where   is the pore size,   is porosity given by    −  , and   is geometric factor 
defined as [115-117]: 
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where   is the fiber volume fraction in Eqn. (4.7). 
The fiber diameter and pore size are closely coupled in the same material as key 
identifying properties. Therefore although taking great difference in expressions, these 
two theories are inherently conjugated. Collagen fiber diameter is at the magnitude of 
nanometers, requiring advanced technique to measure [118]. Collagen hydration and 
fixation state also affects its fiber diameter [119, 120]. On the other hand, collagen pore 
size actually equals to its average fiber spacing at the magnitude of microns. Using 
microscale pore size for calculation makes measurement easier with less error. Therefore, 
local O2 diffusivity in this study will be obtained from the permeability by the “pore size 
theory”. 
4.2.2.2 O2 effective diffusivity in collagen with cells presence 
Since most convection outside the 4QB cartridge is dampened and predominant 
O2 transport takes in the form of diffusion, and therefore local O2 diffusivity controls O2 
delivery to cells. The material-dependent permeability    influences the effective O2 
diffusivity    in porous medium in the way that
†††
 [115]: 
                                                        
x. ††† For other early mathematical equations modeling relation between effective and free diffusivity 
in porous medium, see 113. Swartz, M.A. and M.E. Fleury, Interstitial Flow and Its Effects 
in Soft Tissues. Annual Review of Biomedical Engineering, 2007. 9(1): p. 229-256. 
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( 4.10 ) 
where    is the free O2 diffusivity,   is proportionality constant in porous material (here 
set as 1),    is O2 hydrodynamic radius
‡‡‡
. According to Stokes-Einstein theory, at low 
Reynolds number the hydrodynamic radius    is defined as: 
     
   
   
   
 ( 4.11 ) 
where    is Boltzmann constant and   is absolute temperature. Further, when seeded 
cells have a volume density significant enough to affect O2 effective diffusivity, the 
modified   
  is [121]: 
 𝑒
   𝑒  [ − ( −
 𝑐
 𝑒
) (      5 𝑐
 −        𝑐
2     2  𝑐)] ( 4.12 ) 
where    is cell volume fraction in collagen space. In this simulation, assuming RPHs are 
spheres with uniform diameter at 30 µm, calculation based on current cell density (4-8 
million cells per cartridge) showed such an effect is negligible. 
 
 
FIGURE 4.1 Chart of relations between each parameter, solid line represents direct 
deduction; dot line represents indirect deduction. 
 
 
 
                                                        
xi. ‡‡‡ Hydrodynamic radius is the radius of a sphere the hydrodynamic behavior of which is 
equivalent to interested molecules (e.g. O2 ). 
Pore size/Fiber diameter 
Momentum loss Permeability 
O2 effective local 
diffusivity 
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Fig. 4.1 recapitulates the intricate theories above that how properties of material 
and O2 transport are linked. 
4.2.3 Hepatocytes O2 Uptake Characteristics 
Taking RPHs for example, another challenge in 4QB O2 simulation was how to 
model their O2 uptake rate (OUR). Previous studies modeled the OUR of hepatocytes by 
applying Michaelis-Menten enzymatic kinetics [52, 108, 121, 122]: 
    −     
    [  ]
   [  ]
 ( 4.13 ) 
where     is the volumetric OUR [kg/(s∙m
3
)], the negative sign indicates a sink source, 
      is volumetric cell density (10
6
/m
3
),      is the maximum OUR that can be achieved 
(kg/s), [  ] is the concentration of substrate O2 (in unit of kg O2/kg O2-dissolved 
medium), the Michaelis constant    is the [  ] when the magnitude of     is half     . 
4.3 Methods 
4.3.1 Computational Details 
4.3.1.1 Geometry and mesh 
The space where actual flow happens must be discretized (“meshed”) before 
spatially assigning the physical properties and variables for matrices computing. Due to 
symmetry, only half a quadrant of our 4QB needs to be considered (Fig.4.2). Fig. 4.2 
shows a view of half the 4QB single quadrant CAD model (4 cartridges), built using 
Pro/Engineer Wildfire4 (PTC, Needham, MA) and rendered by Tecplot 360™ (Tecplot, 
Bellevue, WA). Such CAD model was next meshed in ANSYS Workbench, after 
assigning proper boundary conditions it was solved using FLUENT 13.0 (ANSYS, 
Canonsburg, PA). Common geometry-based simplifications include 2D mesh (e.g. by 
axisymmetry) and partitioned 3D unit (e.g. by periodicity) to reduce computational cost. 
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However, as discerned from the design, 4QB single quadrant structure lacks further 
symmetric or periodic feature beyond the one shown in Fig. 4.2. Thus these 
simplifications do not suit 4QB model. The meshed 4QB quadrant geometry duplicates 
from its computer aided design (CAD) model. Within a given quadrant of the 4QB, the 
tissue regions are contained in custom-designed cartridges immersed within medium. The 
medium’s top surface is bound by an air interface and capped by a solid lid above. 
Naturally the 4QB contains air and medium phases. The computational model therefore 
would be ideal to include both phases. It would be also more precise to take account of 
how air affects interface oxygen transport. Each 4QB quadrant has the capacity to 
maintain 8 cartridges, and was tested with 4 million hepatocytes inoculated per cartridge 
[106]. 
 
 
FIGURE 4.2 Half of the 4QB quadrant view in raw Cartesian coordinates for 
computation, and the positioning of each cartridge: are I, II, III and IV from symmetric 
plane to periphery, respectively. Dot line arrows indicate flow direction at inlet and outlet 
 
 
Cartridge  I 
Cartridge  II 
Cartridge  III 
Cartridge  IV 
Symmetry plane 
Top lid 
Inlet 
Outlet 
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4.3.1.2 Model simplifications and optimizations 
Since the 1 mL/s volumetric flow rate in previous 4QB experiments [106] 
generated low Reynolds number flow throughout the bioreactor, computation was 
accomplished in laminar flow mode. The volume of fluid (VOF) scheme [123] built in 
FLUENT ideally should be applied as the key algorithm to distinguish gas-liquid dual 
regions accurately. Only transient mode which progresses the temporal simulation per 
time step was compatible with VOF algorithm. 
However, such dual-phase transient computation requires demandingly great 
numerical stability and is very sensitive to the size of time step. For the best interest of 
CPU-hour, a computation balanced between slim time step around 10
-5
 s and effective 
simulation progressing must be adapted. Adjustments in FLUENT’s explicit transient 
mode with control of Courant-Friedrichs-Lewy (CFL) condition
§§§
 permitted such a 
strategy. Unfortunately, though global Courant number was throttled down to be 1 (see 
APPENDIX A), the practical transient mode computation still failed to converge.  
Another difficulty in transient dual-phase calculation was that the O2 diffusivity at 
air-medium interface is unknown. The air-water O2 interfacial diffusivity couples with 
water surface layer thickness    , as     ⁄      ×   
   /  [124]. Obviously the water 
surface layer thickness    is necessarily to be determined for actual interfacial O2 
diffusivity   . Measuring this property imposed a tremendous challenge and also was 
beyond the scope of this study. Both the numerical stability and interfacial O2 diffusivity 
issues suggested that current modeling needs a substitution for the dual-phase transient 
model, perhaps a simplified steady state model with equivalent accuracy. This model 
                                                        
xii. §§§ Courant-Friedrichs-Lewy condition is a necessary numerical stability gauge for unsteady 
process, see APPENDIX A. 
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based on the same geometry should only contain medium (single fluid phase) and also 
respect O2 diffusion impact from top air boundary. In this steady state model, boundary 
condition at the top lid (Fig. 4.2) is set as a constant O2 diffusive surface acting as if air 
contacting. The effectiveness of such a simplification had been experimentally 
verified.[21] Other reasonable simplifications of the re-established steady-state mode 
included that the isotopic local O2 diffusivity throughout the collagen space; constant 
medium flow at inlet neglecting pulsation introduced by peristaltic pump; and constant 
density of O2-dissovled medium. The main algorithms in FLUENT used for this steady-
state simulation were SIMPLE (acronym of Semi-Implicit Method for Pressure Linked 
Equations [125]) and second order upwind. 
To embed some simplifications in package FLUENT, its user defined function 
(UDF) had been used and attached into steady state model. It had been used in medium-
O2 mixture density control, as O2 “dissolved” in medium is treated by FLUENT with O2 
gas density. It also had been used in solubility control for O2 in medium to avoid unreal 
O2 “accumulation” exceeding the real O2 solubility (see APPENDIX B for source codes). 
 
TABLE 4.1 Major differences between two computational modes: transient mode and 
steady-state mode in computing practice. 
Model Type Transient Steady-state (simplified) 
Phase with free gas-liquid interface without free gas-liquid interface 
Boundary 
free medium top surface as 
opened to air 
bound medium top surface with O2 
diffusion 
Computational 
cost 
~10
5
 iterations and failed to 
achieve convergence  
<10
3
 iterations before convergence 
Hardware 
requirement 
3 octo-core CPUs (24 cores) single quad-core CPU (4 cores) 
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In addition, the 4QB flow region had a complicated geometry and optimizing its 
mesh accelerates the following iteration. For improving mesh quality, meshing functions 
in ANSYS Workbench and ANSYS FLUENT were both utilized. The cartridge’s regular-
shaped collagen space was meshed into hexahedrons in ANSYS Workbench. The free 
medium space was initially discretized as tetrahedrons by Workbench and later converted 
into polyhedrons in FLUENT for taking its advantage [126, 127]. Tab. 4.1 summarized 
the major differences between the previous transient model and simplified steady-state 
model, as comparison. 
Calculated results were post-processed via ANSYS CFD-Post (ANSYS, 
Canonsburg, PA) and Microsoft Excel (Microsoft, Redmond, WA). Contour and other 
results figures were plotted by OriginPro (OrignLab, Northampton, MA). 
4.3.2 Empirical Measurements of Characteristic Parameters 
 
 
FIGURE 4.3: Flow circuit for measuring pressure drop through Biopore PTFE 
membrane. (a) open-flask medium reservoir; (b) peristaltic pump; (c) Three-way “T” 
valve; (d) differential pressure transducer; (e) solid connector with PTFE membrane 
insertion in the middle; (f) Keithley multi-reader; (g) DC power supply; (h) photo of (e) 
(3 replicates). Shadowed arrow indicates the direction of medium pumped through the 
membrane. 
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There were two types of porous materials in 4QB – PureCol
®
 Type I collagen as 
ECM purified from bovine source (Advanced BioMatrix, San Diego, CA), and 
polytetrafluoroethylene (PTFE) porous membrane (Biopore,
 
Millipore, Billerica, MA) to 
entrap cell-ECM assembly and shield cells from detrimental flow shear stress. Both must 
be characterized for computation inputs, which required empirical measurement. 
4.3.2.1 Key inputs for polymer porous membrane 
The 30 μm thick PTFE membrane has the pore size of 0.4 μm [106]. As in theory 
section Eqn.4.5 described, this thin membrane can be perceived by FLUENT as a 
homogenous 1D porous film in computation. Thus two key parameters were required – 
membrane’s permeability and momentum-loss coefficient (Eqn. 4.4 & 4.5). According to 
Darcy’s law (Eqn. 4.6), they can be calculated via pressure drop across the membrane 
and the flow velocity under such pressure drop [114]. Thus experimental apparatus was 
set up as Fig. 4.3 shows: the pressure drop across the membrane was measured using a 
differential pressure transducer (PX170-28DV, Omega Engineering, Stamford, CT), and 
average flow velocity (by the membrane circular cross-sectional area) was determined by 
volumetric flow rate of pump (Ismatec BVK, Cole-Parmer, Vernon Hills, IL). 
4.3.2.2 Approximate collagen gel porosity determination 
Being porous and light, collagen gel is also a tender biomaterial composed of 
nanoscale winded protein fibrils at wet condition [118]. Under normal conditions it 
cannot be sliced or investigated directly under scanning electron microscope (SEM) for 
the sake of moisture. Mercury porosimetry is a very accurate porosity measuring method 
among many [128]. However, this method is hardly applicable to material with great 
deformability. For instance, fibrils of collagen can only bear very little mechanical load 
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and will be damaged during mercury pressurized intrusion. A gentler, gas-based method 
had been developed to measure dry open-pore material’s porosity via applying ideal gas 
law. But not only it requires a unique device with a precise graduation, the error also 
grows since increasing porosity from 30 - 40% [129]. Since collagen is known to have 
porosity of 90% or higher, this method will not be used until its accuracy to high-porosity 
material is confirmed. 
 
  
FIGURE.4.4 Two porous materials in 4QB microscope image (60×). LEFT: 1.3 mg/mL 
polymerized collagen type I fiber spacing and arrangement; RIGHT: PTFE membrane 
polymer/0.4 µm pore distribution (imaged after wet for its transparency). Calibration bar 
(down right corner) is 10µm. 
 
 
An approximate porosity measuring method was thus considered. Note that 
PureCol
®
, had been diluted to desired density 1.3 mg/mL from 3 mg/mL 0.01 M HCl-
dissolved 97% Type I collagen (and ~3% Type III collagen). Diluting supplements for 
this were 0.1 M NaOH solution, 10× Dulbecco’s Modified Eagle Medium (DMEM) and 
deionized water. It was these water-based solutions occupying collagen gel’s porous 
space. It is known that the weight of solution’s aqueous content can be calculated from 
weighed difference of wet and dry collagen. If density of this water portion was assumed 
as that for the solution, the solution’s volume can be estimated by water density at 37°C. 
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Meanwhile, total volume of supplemented collagen solution was already known in 
pipetting. Since porosity is the ratio of porous volume to total volume, if ignoring total 
volume change in polymerization, with estimated porous volume the collagen gel 
approximate porosity (at given conditions 37°C and 1 atm) will be obtained. 
To implement, the weight difference of fresh 1 mL 1.3 mg/mL collagen gel with 
above supplements in P35 before and after vacuum desiccation was measured using lab 
balance (Mettler-Toledo, Columbus, OH). Because collagen gel’s non-protein (solution) 
content was also available from the density (1.3 mg/mL), solution’s rough weight can 
also be calculated to compare with empirical measurements. The calculation showed 
small difference (< 3%). With Eqn. 4.8 & 4.9 given known collagen permeability value, 
the fiber diameter can be deduced from the porosity. Collagen fiber diameter obtained by 
estimated porosity from “differential weights” method agrees with others values [120, 
130], extrapolated or directly match, demonstrated the accuracy of the porosity 
estimation. 
4.3.2.3 Approximate collagen gel pore size determination 
Fiber spacing is a good estimation for pore size of unfixed collagen gel. To image 
fiber distribution, 500 µL 1.3 mg/mL collagen was placed into a Costar
®
 Snapwell™ 12 
mm insert (Corning, Lowell, MA) and incubated at 37°C for 4 hours to achieve full 
gelation and thickness resembling culture in 4QB cartridge. Such insert was imaged 
under an Olympus IX70 microscope with Olympus 60× oil immersed objective (Olympus 
America, Center Valley, PA) and Hamamatsu C4742-95 digital camera (Hamamatsu, 
Bridgewater, NJ). MetaMorph
®
 (Molecular Devices, Sunnyvale, CA) was used as the 
image capturing and processing software. 
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4.3.2.4 Approximate gelatin sponge porosity determination 
When the simulation indicated that only limited O2 local diffusion with 8 million 
cells per cartridge had been permitted, it was imperative to identify the reason. The test 
simulation showed increasing flow rate or membrane removal yielded the same low 
cellular O2 content. Rather, only when collagen gel as original ECM had been replaced 
by Gelfoam
®
 gelatin sponge, cellular O2 content was significantly 
improved.Characterization for this ECM was similar to collagen gel. Its porosity was 
estimated via “differential weights” method by wetting a circular sample piece. 
Specifically, since gelatin sponge is hydrophobic, to saturate it with water, the precisely 
cut sample was placed in a glass jarcontaining deionized water in a 37°C vacuum oven 
(Isotemp
® 
280A, Fisher Scientific, Pittsburg, PA) for fully degassing. Then wet diameter 
and height of the sample were measured for volume calculation. Its net wet weight was 
also measured by same lab balance. Later such a sample was dried using lab vacuum and 
weighed again. The weight difference of gelatin sponge was obtained and its porosity was 
estimated. By this material change, momentum transfer in porous space was altered, and 
consequently so is the effective O2 local diffusivity. Re-simulated results were shown in 
results to compare with the collagen-based results. 
All key parameters used in this simulation are tabulated in APPENDIX A, Tab. 1, 
with descriptions and units. 
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4.3.3 Summary of O2 Balance in 4QB 
 
 
FIGURE 4.5 Illustration of collagen space in a single cartridge that is discretized into 3 
computational grid layers, where computing nodes spread on 4 planes parallel to each 
other. Coordinate system is set cylindrical. C1, C2, C3 and C4 denote O2 concentration 
(in terms of mass fraction) for each nodal plane. Averaged values of paired C2 and C3 
with (r, θ, z) coordinates, where only θ differs, are used to represent O2 distribution in 
each cartridge. Data are presented in cylindrical (Z-R) coordinates:   √      
 
 
 
O2 at inlet in medium was saturated as a result of sufficient oxygenation. The air 
oxygenating effect at air-medium interface was also considered as previously described. 
The Michaelis-Menten kinetics implemented in model was programmed in UDF.which 
set RPHs as the O2-consumping component in cartridge that performs liver function.  
4.3.4 Data Representation for Contour Plots 
Because only O2 values in cartridge interior space were of concern, their data for 
contour plots were selected as shown in Fig. 4.5. Each collagen space entrapped by 
cartridge-membrane assembly has totally 3 layers of hexahedron-structured grids, which 
nodal plane 
C1,  C2,  C3,  C4 
R 
Z 
R’ 
θ 
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yields 4 node layers (Fig. 4.5). O2 concentration at the first (  ) and last nodal layer (  ) 
are boundary conditions for one interested collagen space. The middle two nodal layers 
(     ) represent numerical O2 profile of inside the collagen. In the global cylindrical 
coordinates, the paired values of    and    that have the same (r, z) coordinates (but 
different θ) are averaged into   (i.e.,     
𝐶 
  𝐶3
 
 
       2     ). Such averaged   
values delineate the internal O2 distribution of a single cartridge that cells are sensitive to, 
and thus are plotted as essential O2 results. 
4.4 Results 
The estimated collagen gel porosities acquired by “differential weight” method 
was 92.9 ± 1.3% (n=4, Mean ± SE). While calculation based on collagen solution protein 
density gave 96.0 ± 0.3% (n=4, Mean ± SE), it indicated negligible discrepancy (3%) 
between the two. 
According to Eqn.4.8 & 4.10, the local effective O2 diffusivity for a porous 
material is modulated by its pore size. The ratio of effective O2 diffusivity to free O2 
diffusivity (  /  ) is plotted against material pore size in Fig.4.6. It demonstrates that 
effective O2 diffusivity increases along with pore size enlargement. Such relation is non-
linear: when pore size is comparable to 1 µm, the effective O2 diffusivity is one tenth of 
that in free medium; when pore size is larger than 100 µm the effect of increasing pore 
size to increase O2 diffusivity diminishes (Fig.4.6). This relation implies that an ECM 
with larger pore size will enable higher local effective O2 diffusivity. Applying such 
ECM for higher hepatocytes population can possibly eliminate hypoxia region. 
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FIGURE 4.6. Theoretical relation between ratio of O2 diffusivities (in porous region: in 
free medium) and material pore size (log10 scale), under different porosities (91-97%). 
For all calculated porosities, trends are that when pore sizes are larger, oxygen 
diffusion has less hindrance in porous material. 
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FIGURE 4.7-a: Calculated O2 profiles of cartridge I, II, III and IV, 4 million cells per cartridge, 
collagen gel, in a cylindrical Z-R coordinate. 
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FIGURE 4.7-b: Calculated O2 profiles of cartridge I, II, III and IV, 8 million cells per cartridge, 
collagen gel, in a cylindrical Z-R coordinate. 
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FIGURE 4.8-a: Calculated O2 profiles of cartridge I, II, III and IV, 4 million cells per cartridge, 
gelatin sponge, in a cylindrical Z-R coordinate. 
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FIGURE 4.8-b:  Calculated O2 profiles of cartridge I, II, III and IV, 8 million cells per cartridge, 
gelatin sponge, in a cylindrical Z-R coordinate. 
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The results of a fully loaded, 8-cartridge quadrant (maximally designed capacity) 
are plotted in panel view (Fig. 4.7 & 4.8-a,b). It can be discerned rom the figures that at 
full designed capacity (64 million rat hepatocytes per quadrant), gelatin sponge as an 
ECM with larger pore size (characterized at 350 µm) effectively permits more O2 
transporting into the extracellular space when the overall population is doubled.  
Once ECM switched to gelatin sponge, the O2 supply has been considerably 
improved and the optimized O2 distribution has been increased 12-fold in each cartridge 
on average (Fig.4.9, condition D versus condition B). 
Beside the primary focus on characterizing gelatin sponge as an ECM for 
elaborating its advantage in O2 enhancement, there are still other questions not answered: 
since collagen gel in 4QB is cased in membrane-cartridge structure and protected from 
shear stress, there will be no concern to increase the medium flow rate – will this 
necessarily increase the final O2 level in cartridge? Under normal flow rate (60 mL/min), 
although the PTFE membrane has a substantially larger pore size (0.4 µm = 4000 Å) than 
O2 molecule diameter and is very thin (30 µm), is it also impeding O2 traveling through? 
To investigate cartridge space O2 level under these two conditions, the doubled flow rate 
(120 mL/min) and membrane-free cases were also computed. As shown in Fig. 4.9 
(condition E), double flow rate (120 mL/min) indeed improve the O2 condition even 
slightly more than engineering the ECM material at original flow rate (60 mL/min), while 
removing the membrane (though not feasible in experiment) does not help to raise 
significant O2 in cell-residing cartridge space (condition F). 
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FIGURE 4.9 Average O2 mass fractions in each cartridge (I, II, III and IV). A, B, C, D, E, 
F indicate conditions as: 
A: collagen gel ECM, 4×10
6
/cartridge, original flow rate (60 mL/min); 
B: collagen gel ECM, 8×10
6
/cartridge, original flow rate (60 mL/min); 
C: gelatin sponge ECM, 4×10
6
/cartridge, original flow rate (60 mL/min); 
D: gelatin sponge ECM, 8×10
6
/cartridge, original flow rate (60 mL/min); 
E: collagen gel ECM, 8×10
6
/cartridge, double flow rate (120 mL/min); 
F: collagen gel ECM, 8×10
6
/cartridge, original flow rate (60 mL/min), no PTFE 
membrane. 
A, B, C, and D have the same original flow rate and PTFE membrane, while E has double 
flow rate and PTFE membrane, and F has original flow rate but PTFE membrane was 
removed (in computation). 
To convert the unit here, 10
-6
 = 1 mg O2 / 1 kg mixture ≈ 1 mg O2 /L mixture considering 
O2-contained aqueous medium density is 1.00967 kg/L.[121]) 
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4.5 Discussion 
As a liver-mimicking medical bioreactor, BAL must have the efficiency 
competitive to natural liver for accomplishing the functions. As hepatocytes in BAL are 
inherently aerobic, it is necessary to supply abundant O2 supply into cellular space (i.e., 
ECM’s interstitial space), not just superficially to have O2-enriched medium flow in 
BAL. To improve this O2 condition, the reason casting such a limit must be identified. As 
in ECM porous region where convection is very limited, O2 transport mainly relies on 
diffusion. Therefore, the local effective O2 diffusivity that a particular ECM permits is 
crucial to determine the extracellular O2 content level. 
Previous studies have successfully increased O2 diffusion distance using 
microbeads-embedded collagen ECM [30, 98] and achieved 6-fold viable hepatocytes 
population than normal collagen gel [30, 98]. This agrees with prediction in this chapter 
that the intrinsically low local O2 diffusivity of collagen (causing the short distance O2 
can diffuse in limited time) is the main reason for insufficient O2. At large cell 
population, this issue is aggravated. As Fig. 4.9 summarized, when local O2 diffusivity is 
increased, significant change of O2 profile is achieved as equivalent as double flow rate. 
This implies the low local O2 diffusivity mainly by hindrance of collagen ECM is an 
important cause to mediocre cellular O2 condition in 4QB. Using an alternative ECM 
having higher effective O2 diffusivity could attenuate the O2 issue and remove the barrier 
for higher performance. This has been corroborated in functional results of previous 
CHAPTER 3 (Fig. 4.10, treated by normal medium only): it is demonstrated that using 
gelatin sponge as ECM alone enables C3A cells to have better long-term albumin 
secretion and EROD activity results.  
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a 
 
b 
 
c 
 
  
FIGURE 4.10 (Rearranged CHAPTER 3 results) Results of Albumin secretion (a), 
glucose reduction (b) and EROD activity (c) in static plate culture, collagen gel ECM 
compared to gelatin sponge ECM. n=9, Mean ± SE, *:p<0.05 (adapted from Fig. 3.4 I & 
II). 
 
 
 
As simulated results indicate, gelatin sponge with larger pore size is a promising 
candidate to solve O2 issue in 4QB cartridge. When simulated again setting gelatin 
sponge as ECM, the results showed that on average 12-fold O2 content has been achieved 
at 8 million cells per cartridge than previous predicted O2 distribution (Fig. 4.9). By its 
success, the model has allowed us to avoid high “trial-error” costs associated with real 
experiments. 
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In addition, to prove accuracy and effectiveness of the model, it would be ideal to 
introduce O2 sensor into our cell-seeded 4QB and compare the acquired O2 concentration 
data with numerically predicted results. An ideal sensor would feature such properties as: 
easy to handle and mount; small but with high sensitivity, for O2 varies spatially in 4QB 
and usually its concentration is low; and preferably with low maintenance. The size of 
traditional O2 probe (polarographic, Clark-type or Galvanic) would trouble its fitting into 
the small celluar space (such as that in 4QB cartridge) and have a high spatial definition. 
An alternative method is to use the O2 optode incorporating optic fiber and measures O2 
based on luminescence which does not consume O2 [20, 21]. The clear advantages of 
such optode are tiny size that allows insertion of small space, and zero O2 consumption 
which leaves original O2 state undisturbed. Though this measurement is beyond the scope 
of this study due to the cost and experimental limitations, its effects in impending 
research publications are highly expected. 
 
CHAPTER 5: PERFORMANCE OF RAT HEPATOCYTES DRUG METABOLISM IN 
3D CULTURE AND DYNAMIC FLOW DEVICES 
5.1 Introduction 
Drug detoxification is one of the most important functions of hepatocytes. Drug, 
mostly lipophilic, is apt to affix cell membrane and thus retain in human body to form 
unwanted toxins. To clean the unnecessary drugs that dwell in human body, the cleansing 
mechanism in human liver plays a crucial role. Drug metabolism by hepatocytes 
biochemically transforms such foreign chemicals into hydrophilic compounds (via 
hydroxylation) which are more soluble in water (and blood stream). General formula of 
such biotransformation for drug is as below [22, 26]: 
              
𝐶 𝑃   
→                    ( 5.1 )  
where RH is the drug to be transformed, NADPH is the co-factor nicotinamide adenine 
dinucleotide phosphate. In this type of reaction, molecular O2 also serves as electron 
acceptor as it is in energy metabolism. Specifically, one oxygen atom is used in 
hydroxylating RH into ROH, the other atom accepts hydrogen atom and forms water H2O 
(Eqn. 5.1). As a result, drug is biotransformed into more hydrophilic compounds and its 
excretion is facilitated (via urination, perspiration etc.). In hepatocytes, such 
biotransformations are catalyzed via a superfamily of enzymes – cytochrome P 450 
(CYP450). Each specific type of CYP 450 hydroxylates a certain category of substrates.  
In this chapter, the drug metabolism function of rat hepatocytes (RPHs) were 
evaluated in different extracellular matrices (ECM) under static and dynamic flow 
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conditions, to investigate how different oxygenation conditions particularly impact the 
catalyzing efficiency of CYP450 (i.e., CYP450 activity). Such functions were tested 
under different cell seeding populations, as a specific aim of future’s BAL is to achieve 
higher capacity for which the BAL demands more densely packed cells as researchers 
striving to attain [15]. Specifically, to activate such enzymes, two polycyclic aromatic 
hydrocarbons (or polynuclear aryl hydrocarbons, PAHs): 2,3,7,8-tetrachlorodibenzo-p-
dioxin (TCDD), the most potent dioxin, and 3-methylcholanthrene (3-MC), also a strong 
carcinogen, were supplemented in medium as inducers to stimulate CYP450 enzyme 
activities. These enzyme activities were measured by ethoxycoumarin (EC) and 
ehtoxyresorufin (ER) which are substrates for ethoxycoumarin-O-deethylase (ECOD) and 
ethxyresorufin-O-deethylase (EROD) assays, respectively. The hydroxylation rate of 
substrates in each assay was regarded as the indication of ECOD/EROD activity. 
Advantages of gelatin sponge as ECM and dynamic flow conditions were demonstrated 
in results having notably higher RPH CYP 450 activity as contrast to the control. Also, 
the encountered issues were analyzed and possible causes to them are discussed. 
5.2 Materials and Method 
Following previously established procedures, hepatocytes were isolated from 
Sprague-Dawley male rats weighing 150-280 g that were fasted 24 hours prior to 
isolation [131]. The viability of received hepatocytes was accessed immediately using 
Trypan Blue exclusion assay (Sigma-Aldrich, St. Louis, MO). For each experiment, 
hepatocytes with viability higher than 90% are used, otherwise the cells were Percoll
®
- 
centrifuged (GE healthcare, Waukesha, WI) to screen out dead cells until viability 
reaches higher than 90%. 
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The regular cell culture medium bases on Gibco
®
 William’s E medium (Life 
Technologies, Grand Island, NY) was supplemented by 10% (v/v) standard fetal bovine 
serum (HyClone, Thermo Scientific, Waltham, MA) and 1% (v/v) antibiotic/antimycotic 
solution (JR Scientific, Woodland, CA).Separate inducers (TCDD or 3-MC) were added 
to this regular culture medium to initiate different function assays (EROD or ECOD, 
details elaborated in assay section). 
5.2.1 Cell Culture 3D Configuration 
5.2.1.1 Collagen dispersion configuration 
PureCol
®
 collagen (containing 98% Type I collagen) at the concentration 3.1 
mg/mL was diluted down to 1.8 mg/mL using 1/8 final volume of 10× Dulbecco’s 
Modified Eagle Medium (DMEM). To prepare the collagen for entrapping RPHs in 3D 
space, 1.8 mg/mL collagen was pre-warmed in 37°C water bath for 2-10 minutes 
(depending the volume) till a significant higher viscosity was achieved yet no gelation 
started. Meanwhile, quantified cell solution was pelleted and evenly mixed with 
proportional pre-warmed viscous collagen, forming desired uniform cell density (2 
million/mL or 4 million/mL). Subsequently, 1 mL of such homogenous cell-collagen 
mixture was pipetted into each well of a standard 12-well plate to obtain 2 or 4 million 
cells per well density, and incubated at least 3 hours for full gelation. After firmly gelled, 
each cell-collagen sample was added 2 mL regular culture medium and incubated for 
another 24 hours after when 2 mL inducer-medium (TCDD or 3-MC) replaced the 
regular medium in each well and cultures were returned to incubation for one more day 
(day 2). Drug metabolism assays (ECOD, EROD) were performed on day 2. 
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5.2.1.2 Gelatin sponge configuration 
Gelfoam
®
 (Pharmacia & Upjohn, New York, NY) gelatin sponge dry sheet (the 
same scaffold applied in CHAPTER 3) was cut into discs with radius of 16 mm (same as 
inner diameter of standard 15 mL conical tube) and sterilely hydrated using same method 
in CHAPTER 3, for culture in standard 12 well plate. The same cell population (2 or 4 
million per disc) was also implemented to this type of ECM culture. 
5.2.2 Drug Metabolism Assays 
5.2.2.1 Ethoxycoumarin O-Deethylase (ECOD) assay 
For static plate culture, previously induced 3D cell collagen-suspension or cell-
loaded sponge discs were placed in 12-well plate cell culture units. Each unit was 
induced by 2 mL of 10 nM TCDD conditioned culture medium since day 1 and last for 
24 hours. Then supernatant of each well was aspirated and each sample was added 3 mL 
Hank’s Balanced Salt Solution (HBSS) and incubated 20 minutes for rinsing. After 1.5 
mL 100 µM 7-ethoxycoumarin (7-EC) in serum-free William’s E medium was added as 
substrate, and all samples were incubated for 1 hour. Each sample was pressed in culture 
well using a syringe plunger until all free 7-EC solution has been collected into a 2 mL 
Eppendorf vial (Fisher Scientific, Pittsburgh, PA). Collected original sample solutions 
were stored at -20C till use. 
As the start, the first step is to directly extract the net 7-hydroxycoumarin (7-HC) 
in solution. Each 0.5 mL original sample solution was added 1 mL chloroform (Sigma-
Aldrich, St. Louis, MI) and vortexed for 30 seconds, then centrifuged at 2000 g for 7 
minutes. Then 0.5 mL of 7-HC dissolved chloroform was transferred to a clean 2 mL 
eppendorf vial and added 1.25 mL 0.01 M NaOH/1 M NaCl, vortexed and centrifuged 
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again (3 minutes instead of 7 minutes). At the end, 1 mL of the 0.01 M NaOH/1 M NaCl 
solution in each vial (final 7-HC solution) was pipetted in plastic cuvette (Fisher 
Scientific, Pittsburgh, PA) and read by a F-2500 fluorescence spectrophotometer 
(HITACHI, Tarrytown, NY) with excitation/emission at 360/450 nm. Concentrations of 
the 7-HC were determined via comparing the readings of known 7-EC standard curve 
such that final 7-HC amount of each sample was calculated using dilution ratio in 
extraction. 
In order to measure all 7-EC including that also has been biotransformed phase II 
drug metabolism, 0.5 mL 100 units/mL β-glucuronidase (Sigma-Aldrich, St. Louis, MO) 
solution
****
 was mixed with 0.5 mL original sample solution in the same 2 mL eppendorf 
vial. Each vial with such mixture was shaken in water bath for 3 hours, and the same 
extraction and reading steps were performed. Data from both forward (drug metabolism 
phase I) and reverse reaction (phase II) were summed to evaluate the total 7-EC 
generated via hydroxylation (i.e., the ECOD activity). For dynamic culture (plate & tube 
devices) and the static tube culture (as control for tube device), except that the induction 
part was completed in flow-perfused device, the rest of the assay was identical to that in 
static plate culture described above. 
5.2.2.2 Ethoxyresorufin O-Deethylase (EROD) assay 
Similar to ECOD assay, for static culture, after 48 hours of sample units cultured 
in 2 µM 3-MC medium (refreshed once at 24-hour time point), each sample was rinsed in 
3 mL HBSS for 20 minutes. Then 1.5 mL 10 μM ethoxyresorufin (ER) and 10 µM 
dicumarol in 50 mM HEPES buffer was added following 1 hour incubation. At the end, 
                                                        
xiii. **** This concentration is diluted from 840 units/mL (1.4 mg/mL) β-glucuronidase stock using 60 
mM sodium acetate (Sigma-Aldrich, St. Louis, MO) solution. 
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as in ECOD assay, maximum volume of free ER solution was collected (for sponge 
culture the disc was pressed), and was stored at -20C until use. The reading was taken at 
excitation/emission of 530/590 nm using the same HITACHI spectrophotometer. Similar 
to ECOD assay, for dynamic culture and the static tube culture, except that the induction 
part the rest of the assay was also kept identical as that above. 
For both ECOD and EROD assays, the inducer-free regular medium cultured 
groups were used as negative control (supposed to be blank), and their readings were 
subtracted from the readings of sample group (i.e., the inducer supplemented 
medium).Therefore, all results recorded had considered normal medium effect to 
CYP450 activity. 
5.2.3 Flow Devices used in Dynamic Cell Culture 
 
 
FIGURE.5.1 Schematic of the flow device based on regular 12-well tissue culture plate 
(plate device). (a): incubator; (b) standard 12-well plate with each well serially connected 
at bottom; (c) cell-loaded gelatin sponge disc; (d) flow direction maked as arrowed dash 
line; (e): peristaltic pump; (f) silicone tubing (except for pump-pressed portion). 
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To investigate the effects of flow condition to RPHs’ drug metabolism, two 
distinct flow devices were designed and used for this study: flow device No.1 is based on 
a 12-well cell culture plate (“plate device” ), and device No.2 is based on a 15 mL conical 
tube (“tube device”). Medium flow of both designs was driven by the same peristaltic 
pump (Cole-Parmer, Vernon Hills, IL) at certain rates. 
5.2.3.1 The plate device 
The plate device relies on the same passive oxygenating mechanisms that regular 
multi-well plates does. Modified from a regular 12-well cell culture plate, such plate 
device can house 4 separate samples at one time. Having its wells of each column 
punched through at the bottom and was connected serially by tubing segment (Fig. 5.1), it 
enables medium flows from the 1
st
 well to the 3
rd
 well in the same column and culture the 
cell-loaded sponge disc was placed in the 2
nd
 well (Fig. 5.1, middle well), in a 
“circumventing” manner. 
At the 1
st
 and 3
rd
 well, fittings were used to connect the medium-supplying tubing 
and interior well space as inlets and outlets. Sealing of all junctions is done via silicone 
sealant (IS 808, Momentive Performance Materials, Waterford, NY). The medium-supply 
tubings are made of silicone to permit sterile O2 diffusion from air aside that through top 
cover. After drilling, accessories attaching and sealing of the plate had been finished, the 
whole plate device was soaked in 70% ethanol for 1 hour then dried in laminar flow hood 
under ultraviolet (UV) light. Prior to culture, 12 mL of medium was slowly added to each 
column, ensuring the whole cell-loaded gelatin sponge disc in the 2
nd
 well (middle well) 
would be fully immersed at flow running (Fig. 5.1). The main advantage of this device is 
that since most of the flow circumvents around the disc, the shear stress generated within 
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the disc structure is minimized, while the culture-surrounding medium was always 
agitated to optimize O2 and nutrient condition. As the O2 delivery in such a device 
derives from the passive diffusion static plate culture relies on, plus O2 also diffuses from 
circuit’s silicone tubing, at given cell population O2 supply in plate device is not a 
concern. 
 
 
FIGURE.5.2: Schematic of the flow device based on regular 15 mL conical tube (tube 
device). (a)syringe filter; (b)15 mL conical tube; (c)cell-loaded gelatin sponge disc; 
(d)stainless steel mesh; (e)incubator; (f) gas exchanger; (g) peristaltic pump; (h) gas tank. 
(A)&(B): syringe sampling ports for measuring O2 at outlet & inlet of tube flow device  
 
 
 
5.2.3.2 The tube device 
In the plate device, the sponge disc-circumventing medium lacked the momentum 
to force fluid through cellular region and a poor perfusion was foreseen. To regulate the 
flow going thoroughly into the sponge disc interstitial space, previous conical tube-based 
flow device in CHAPTER 3 is redesigned to apply to current flow study. Sharing a large 
portion of design features as the flow device in CHAPTER 3, this 15 mL conical tube-
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based device has smaller diameter (16 mm) to house the 3D cell-loaded sponge disc with 
the same size of discs in 12 well-plate static culture and plate device culture, meanwhile 
allowing vertical medium perfusion. This size shrinkage offers more calibrated 
parameters and costs less expensive gelatin ECM material than previous device design in 
CHAPTER 3. Since in vitro RPHs do not proliferate, quantitating their number becomes 
more convenient. Cells were seeded at the same density (2 or 4 million per disc) as in 
static plate culture. This is a considerably higher density than that implemented in 
CHAPTER 3, in which replicating C3A cell line having a smaller OUR [103] was used. 
5.2.4 O2 Measurements for Tube Flow Device 
As previously mentioned, the prototype of tube flow device shown in Fig. 5.2 was 
firstly tested in CHAPTER 3 for PFC study. Here it is modified into a smaller version 
with reduced size of 3D culture. The actual O2 situation of either case, however, was not 
measured. As RPHs consumes O2 considerably faster than HepG2 cell line especially in 
dynamic flow condition [103] and this smaller tube flow device was going to 
accommodate a lot more cells (up to 4 million per device), it is imperative to validate the 
O2 condition in flow device with cell presence. A straightforward method to attain this is 
to measure the O2 concentration in medium outflow (spent medium). 
5.2.4.1 Relation between O2 concentration and partial pressure (pO2) 
Henry’s law states that with temperature held constant, molar concentration of a 
gas as solute in dilute liquid solution (i.e., far from saturated) is proportional to the gas’s 
partial pressure equilibrated to this liquid, and the proportionality is the Henry’s constant 
[132] (also named “gas solubility” in literature). Henry’s constant varies when 
temperature changes in the way the van’t Hoff equation (Eqn. 5.2) describes [133]: 
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)] ( 5.2 )  
where    is Henry’s constant at temperature  , and     is that at standard temperature    
(e.g. 25ºC or 298K),   is constant depending on gas species, and for O2 it is 1700. 
Acocrding to standar Henry’s constant at 298K is 1.3×10
-3
 mol/(L∙atm) and Eqn. 5.3, for 
O2 in aqueous solution at 37ºC Henry’s constant is 1.042×10
-3
 mol/(L∙atm) [1.371×10
-9 
mol/(mL∙mmHg)]. This value closely agrees with that has been used in literature 
[1.29×10
-9 
mol/(mL∙mmHg)].[103] To comprehend the DO probe-measured O2 
concentrations in unit of mg/L in a sense of the in vivo physilogical pO2 data with unit 
mmHg (Torr), Henry’s law must be applied. 
5.2.4.2 OUR determination 
Meanwhile, the O2 uptake rate (OUR) in this particular device was also of interest. 
Together with flow rate, this value could also be acquired via the difference between O2 
concentrations at inlet and outlet, as in Eqn. 5.3: 
    
 (    −      )
 
 ( 5.3 )  
where   is perfusion flow rate (mL/minute),      is the O2 concentration at tube device 
inlet (mg/L) and       is that at outlet (mg/L),   is cell population in device (10
6
). 
For measuring, two T- connectors were mounted at illustrated positions in Fig. 5.2: “A” 
before gas exchanger and the other “B” after gas exchanger. Each connector was 
connected to a 3 mL syringe as sample receiver. The tube flow system was allowed to run 
as the same assay inducing period (1 day of TCDD-medium and 2 days of 3-MC 
medium). At the end of such dynamic culture, medium flow toward gas exchanger was 
redirected to syringe at “A”, and 3 mL sample solution was collected, volume as 
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minimally required by our dissolved oxygen (DO) meter (AccumetXL60, Thermo Fisher 
Scientific, Waltham, MA) to measure its O2 concentration in the same way as CHAPTER 
2 describes. 
The measured 3 mL medium did not return to the device. Instead, equal volume 
fresh inducing medium were injected back to flow device via the sampled syringe as 
compensation. During measuring time, the pump was stopped till medium compensation 
was done, then resumed running to allow re-equilibrium for 20 minutes. The same 
sampling steps were performed again at “B” to evaluate freshly re-oxygenated medium. 
Readings were taken once stabilized, as previously described in CHAPTER 2. 
Immediately after completion of O2 measurements, cell-loaded sponge discs were 
retrieved from each flow device and controls (static tubes) into 12-well plates, and 
ECOD/EROD assays were then performed. 
5.2.5 Flow Rates Setup 
The flow rate of circulating medium was 0.82 mL/min in the plate device 
experiments. This rate seems arbitrary but in fact it is easily scaled up or down as it is set 
by peristaltic pump at 10 rpm
††††
. The flow rate of the tube-device was set as 0.41 
mL/min (5 rpm), to avoid unexpected shear stress condition, as well as to accommodate 
single sponge disc’s hydraulic permeability. 
5.2.6 Plotting and Statistical Analysis 
The O2 measurement of the device was repeated 3 different times. Each ECOD 
and EROD assay experiment consisted of at least 4 samples (static plate, collagen 
dispersion and gelatin sponge) or 3 samples (dynamic plate- and tube-devices). Each type 
of experiment was independently performed 3 times. Results are presented as Mean ± 
                                                        
xiv. †††† This peristaltic pump has the rpm range 0-999 rpm. 
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Standard Error (SE). One-way analysis of variance (ANOVA) was performed and p < 
0.05 is regarded as judge criterion for statistical difference. OriginPro (OriginLab, 
Northampton, MA) was used to plot the data as well as to perform the statistical analysis. 
5.3 Results 
5.3.1 O2 Measurement for Tube Flow Device 
 
 
FIGURE 5.3 O2 concentrations at inlet and outlet at two different inducer conditions and 
two perfusion flow rates (0.41 and 1.64 mL/min), in tube flow device as shown by Fig. 
5.2. n ≥3, Mean ± SE. 
 
 
 
Fig. 5.3 illustrates measured different O2 concentration levels at tube flow device 
inlet and outlet, at different . Since the main purpose to examne this O2 condition is to 
make sure no obvious O2-defficient flow occurs during the inducing period, only the 
minimum O2 concentration should be examined. As Fig. 5.3 shows, the minimum O2 
pO2 =91.14 mmHg 
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concentration (TCDD medium treated , outlet) is higher than 4 mg/L. Using Henry’s law 
to convert 4 mg/L and obtain the equilibrated pO2 level at 91.14 mmHg (Torr), it can be 
concluded that the average supply and spent media pO2 levels were all above this value.  
Tab. 5.1 shows the OUR results calculated from Eqn. 5.3 for different inducer 
conditioned media. Among all results in Tab. 5.1, no statistical significance was found. 
 
TABLE. 5.1 O2 uptake rates (OUR) of RPHs in custom designed flow device compared 
with value from literature. The measured original O2 concentration unit was mg/L. In 
order to compare with results in [103] data unit were converted in to µmol/L. 4-MU 
stands for 4- methylumbelliferone. 
Device type 
Total RPHs 
population 
Flow rate 
(mL/min) 
Inducer in medium 
OUR  
(µmol/10
6
-hour) 
(Mean ± SE) 
Flow device in 
Fig. 5.2 
1×10
6
 
0.41 
10 nM TCDD  2.36 ± 1.28 
2 µM 3-MC 2.46 ± 0.29 
1.64 
10 nM TCDD  6.15 ± 0.81 
2 µM 3-MC 5.84 ± 1.27 
Hollow fiber 
bioreactor in 
[103] 
1×10
8
 0.15 
5 µg/mL Lidocaine 
and 60 pM 4-MU  
0.173±0.021 
 
 
 
5.3.2 CYP450 Functions 
For static plate culture, the 2 million cells in both collagen gel and gelatin sponge 
ECMs had ECOD activity on the same level (Fig. 5.4-Ia). Yet when population increased 
to 4 million, it was the gelatin sponge-cultured hepatocytes that had a higher rate of 
catalyzing the EC-HC transformation. Such a phenomenon also exist in static plate 
culture EROD assay (Fig. 5.4-IIa), where hepatocytes in gelation sponge matrix has 
higher EROD activity.  
However, for the above populations under flow condition, neither enzyme (ECOD 
or EROD) of hepatcoytes cultured in plate device showed higher activity than static 
culture. Rather, though both cultured in the same gelatin sponge ECM, the EROD activity 
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of cells embedded in dynamic flow-surrounded sponge disc of plate device even fell 
below the level that static plate cultured hepatocytes had (Fig. 5.4-IIb).  
For tube device, activities of these two CYP 450 enzymes were contrasted to the 
hepatocyte sponge culture in a tube having no flow (static tube). The ECOD result of 
population at 4 million per disc demonstrated that at such a higher cell density, 
hepatocytes in flow device had a higher EC-HC catalyzing speed than the static control. 
Fig. 5.4-IIc shows the EROD assay results for both dynamic tube device and its 
static tube control. Nonetheless, similar to the phenomenon in Fig. 5.4-IIb, for both 2 
million and 4 million cells per sponge disc, static tube allowed hepatocytes to perform 
EROD function better, and this was even more obvious in the case of 4 million cells per 
disc.  
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 I II 
a 
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c 
  
FIGURE 5.4: ECOD (column I) and EROD (column II) activities of rat hepatocytes. Row 
a: comparison of static cultures in collagen dispersion and gelatin sponge (n = 12); Row 
b: comparison of static culture in gelatin sponge (n=12) and plate device dynamic culture 
(n=4); Row c: comparison of cultures in static tube and dynamic tube device (n=4). Mean 
± SE *: p<0.05. 
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5.4 Discussion 
In this study, the O2 concentrations at the inlet and outlet of a conical tube based 
device were measured, from which the OUR per million of RPH in such a device was 
determined. More importantly, the activities of two specific CYP 450 enzymes – ECOD 
and EROD – were evaluated under 3D gelatin sponge ECM and dynamic flow conditions 
with two different seeding densities assigned to each assay. 
Firstly the O2 concentration levels at inlet and outlet of the tube device to be used 
for CYP450 fucntion study were measured, to guarantee that the gas exchanger was 
effecitvely re-oxygnating the circulating medium. Considering the pO2 in average liver 
periportal blood ranges 60-65 mmHg and in perivenous blood it is 30-35 mmHg [134], 
the minimum pO2 value derived from Fig. 5.3 (91.14 mmHg) ensured that the O2 supply 
in the flow device will be fairly abundant through the perfusion period at inducer 
presence. 
When the same data were used to characterize OUR between two distinct flow 
rates tested (0.41 and 1.64 mL/min) for the same inducer type in Tab. 5.1, there was 
actually no statistical significance found. However, the climbing average OUR values 
along increasing flow rate suggest that with in a moderate range, higher flow rate (i.e., 
higher O2 availability) may encourage cells to consume more O2. This trend agrees with 
Michaelis-Menten enzyme kinetics theory (see CHAPTER 4), previous OUR studies 
perfusing ex vivo rat liver [135] and isolated hepatocytes [136, 137]. 
ECOD and EROD results in static culture suggested that for both assays, when 
hepatocytes were cultured at higher density, gelatin sponge-seeded cells demonstrated 
higher CYP 450 activities than cells dispersed in collagen gel. This may attribute to the 
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different ECMs been used and the different configurations such ECMs necessarily 
introduced. For example, in collagen dispersion, though cells were also suspend in 3D gel 
trap (Fig. 5.5, left), as 1 mL cell-collagen mixture was plated in culturing well, forming a 
gel layer with height of ~2.5 mm from bottom, O2 supply to all cells through this layer 
has to be through the top layer of medium and then reaches the collagen region. As a 
contrast, the gelatin sponge having a larger volume holds the same number of cells. 
Therefore its actual cell volume density is less than the dispersion (Fig. 5.5, right). 
A more important positive aspect of the gelatin sponge material is that due to a 
higher O2 local diffusivity it permits (as analyzed in CHAPTER 4), cells have the 
opportunity to consume more O2 transported into their neighborhood. As a result, their 
CYP 450 activities were enhanced. Thus the advantage of gelatin sponge for cell 3D 
cultivation ECM has been proved again in static drug metabolism related experiments 
(for more comparison, see CHAPTER 3). 
 
 
FIGURE 5.5. Schematic of two static culture configurations in 12-well standard plate 
(not to scale). LEFT: cells in collagen gel dispersion; RIGHT: cells in gelatin sponge. 
 
 
 
When comparing both static and dynamic plate culture using the same gelatin 
sponge as ECM, the results were seemingly confounding: in ECOD assay as no statistical 
difference was found between the static and dynamic plate culture (Fig. 5.4-Ib). If this is 
because flow did not sufficiently perfuse through the sponge disc central region in plate 
Cell culture medium 
Cell-ECM region 
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device, same justification cannot explicate that the EROD counterpart had weaker CYP 
450 activity in dynamic plate culture than static plate culture, for both populations (Fig. 
5.4-IIb). 
Similar phenomenon continued: when EROD results are revisited, it is shown that 
neither population at dynamic condition yielded higher resorufin production rate per 
million cells than those in static tubes. Initially it was assumed that the shear stress in 
dynamic tube may have reached the deleterious level, as RPHs have a low threshold to 
bear shear stress above which their function performance will be weakened (0.5 Pa in 
normal hepatic sinusoids) [138] (more shear stress discussion in APPENDIX C). 
However, the shear stress in plate device that has non-perfusive flow should not impose 
sensible shear stress to cells, particularly when most of them were seeded in the disc 
central region where motionless flow can be expected. 
 
TABLE. 5.2 Levels of drug inducer (TCDD and 3-MC) as toxin and flow rates in each 
type of RPH cultures. 
Culture 
configuration 
Medium 
volume per 
culture 
(mL/unit) 
10 nM TCDD 
amount 
(nmol/10
6
) 
2 µM 3-MC 
amount 
(nmol/10
6
) 
Flow rate 
(mL/min) 
Estimated 
extracellula
r shear 
stress level 
2×10
6
 
cells 
4×10
6 
cells 
2×10
6
 
cells 
4×10
6
 
cells 
Static plate 2 0.01 0.005 2 1 - zero 
Dynamic plate 12 0.06 0.03 12 6 0.82 minimum 
Static tube 8 0.04 0.02 8 4 - zero 
Dynamic tube 24 0.12 0.06 24 12 0.41 
moderate to 
high 
4QB [106] 
40 
(per 
cartridge) 
- 
20  
(32 ×10
6
 cells) 
60 
zero/ 
minimum 
 
 
 
One possible cause to the deteriorated EROD activities in both devices is likely to 
be the excessive 3-MC amount per cell was added, which was not effectively metabolized 
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and exerted remarkable toxicity. Placing quantities of both TCDD and 3-MC inducers 
under review, for ECOD assay it was10 nM TCDD medium while in EROD assay the 
concentration of 3-MC was 2 µM. Both concentrations were consistently used in all types 
of static culture and dynamic culture. However, in the two flow devices, a greater volume 
(plate device: 12 mL; tube device: 24 mL) was required, such that total toxin levels were 
significantly increased (Tab. 5.2). For example, in plate device, TCDD and 3-MC 
quantities per million cells are 6 times of those in static plate (Tab. 5.2). Among all types 
of cultures, normalized TCDD amount was sustained below 1 nmol per million cells, 
while 3-MC dramatically increased from 1 up to 24 nmol per million cells. This 3-MC 
quantity may contribute to the fact that cultured hepatocytes were not only induced, but 
also overwhelmed by its toxicity and had suppressed metabolic activity or even lower 
viability. 
But such level of 3-MC was already used in previous study , resulting up to 20 
nmol per million cells for cartridge-entrapped RPHs [106] (Tab. 5.2), the question thus 
now becomes why previous dynamic 4QB cultured cells had a higher EROD activity than 
its control: the 24-well plate cultured cells (Fig. 5.6). 
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Figure 5.6 Ethoxyresorufin O-deethylase activity of hepatocytes before placement in the 
bioreactor (day 2 after isolation) and after (days 9 and 15). The values are the mean±SD, 
n=3.Statistically significant difference: *p<0.05.Reproduced from [106]. 
 
 
 
It is believed that the answer also lies in the diffusion hindrance theory. In 4QB 
the cell-embedded collagen may have hampered not only the diffusion of O2 molecules, 
but also the loading rate of 3-MCmolecules as well. Though there was convective flow in 
chamber for long term, according to the universal diffusion hindrance elaborated by 
Stokes-Einstein theory in CHAPTER 4 (Eqn.4.10), the 3-MC diffusion rate into cellular 
space was actually also throttled. In this case, the cellular CYP450 enzyme had been 
catalyzing the reactant 3-MC with an appropriate supply rate. As there was no 3-MC 
accumulation, its toxicity also diminished. On the contrary, the gelatin sponge has 
characteristic pore size more than 30 µm [80] and permits a high mass transport rate  for 
general substances including both O2 and 3-MC. With such enhanced diffusivity enabled, 
both 3-MC and O2 delivery into the interstitial space of gelatin sponge were facilitated. 
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More 3-MC, as far as available, entered cytoplasm directly and stressed the entire 
hepatocellular metabolism. To confirm this adverse “overdosing effect”, one method is 
using relevant cytotoxicity assays [such as almarBlue
®
 (resazurin)] to check cell 
metabolic responses under different 3-MC concentrations, which starts to be reduced 
from 2 µM. 
Since design and design-determined circulating volume varies from device to 
device it is difficult to immediately select an optimal inducer concentration for function 
study. Therefore, in the future bioreactor CYP450 study, it would be always prudent to 
use a diluted inducer concentration from culture condition that has lower volume (e.g., 
petri dish culture), and adjust dynamically according to the feedback. 
CHAPTER 6: CONCLUSION AND REMARKS FOR FUTURE WORK 
Initiated with the intention to bridge FHF patients, over the past 40 years BAL has 
yet to be approved by regulatory agencies [8]. As a future medical device, a myriad of 
challenges regarding BAL applicability to clinical therapy or pharmaceutical test need to 
be overcome, including establishing design standardization and manufacturability, 
efficacy of distinct cell sources, and availability of any chosen cell source. However, 
because the throughput level of BAL determines radically how well it performs function, 
the most critical factor barring its clinical and industrial applications is the efficiency that 
protrudes as a fundamental problem awaiting solutions. Hepatocytes, primary or 
genetically derived, have a high demand of O2 despite that the levels may vary. This trait 
suggests that one possible solution to BAL’s efficiency issue is to supply more O2 into 
the BAL kernel reacting region and evaluate how much efficiency melioration has been 
received under such condition. Advancing to this answer is the ultimate aim that this 
dissertation strives to serve. 
The study in CHAPTER 2 characterized the O2 absorption profile a commercially 
prepared Oxycyte
®
 (effective compound: PTBCH) for the first time. Main purpose of this 
is to take advantage of the high O2 affinity of this new PFC product for O2 
supplementation in a 3D thick hepatic culture. The fact that under the same pressurizing 
system, 5% PFC-medium (MEM based) may carry significant higher O2 content than its 
10% competitor was a surprise, as on the contrary it was conventionally believed that 
more PFC fraction in aqueous emulsion assist to carry more O2. This specific 
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phenomenon coming from measured results was discussed in CHAPTER 2, and possible 
default DO probe device setting that only applies to pure aqueous solution was deemed 
contributing to this deviation. 
In CHAPTER 3 the commercially prepared Oxycyte
®
 was applied to both static 
and dynamic hepatic culture, for assessing its efficacy on cell metabolism and functions. 
C3A human hepatoblastoma cell line was selected as the subject for this PFC efficacy test 
and gelatin sponge product Gelfoam
® 
was used as the 3D scaffold. This 3D ECM 
supports cells anchorage and suspends them spatially to experience incoming PFC fluid 
perfusion. A great advantage is demonstrated by such in vitro organoid system: it can 
examine the PFC’s separate effects to hepatic cells by moderate simplification with other 
unwanted intriguing physiological restrictions excluded. Although CO2 highly dissolved 
in Oxycyte
®
 [139], some PFCs are reported having low CO2 solubility and if tested 
during in vivo perfusion may cause hypercapnia [140]. Other side effects when PFC is 
instilled to animal or human subject for administration also include thrombocytopenia 
[141]. 
In this in vitro organoid system the 3D gelatin scaffold that is necessary to the 
flow system and controls, however, somewhat perplexed the analysis to PFC independent 
effects to cells. As Fig. 4.10 illustrates, the 3D gelatin sponge scaffold alone had already 
promoted albumin synthesis of C3A cells and further addition of PFC (Oxycyte
®
) into 
static culture and dynamic culture did not extend this promotion (Fig. 3.4-IIa & Fig. 3.6-
a). Considering the genetic alteration of C3A inherited from HepG2, it is likely that 
improvement in Fig. 4.10 had approached the paramount of C3A albumin expression in 
static culture that can be affected by O2 alone. To C3A cells, the benefit of more O2 to its 
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functionalities was manifested more on their activity of EROD, a representative CYP 450 
enzyme, and meanwhile flow condition must be accompanied. External comments used 
to be received questioned if this CYP450 function improvement could be resulted from 
unidentified Oxycyte
®
 cytotoxicity. Yet since in general PFCs are nonpolar (lipophobic) 
compounds that are and do not dissolve in cell membrane, either it is difficult to believe 
or to date there is no documented evidence indicating that PFC can participate in 
metabolism within cellular compartments. A separate and complete Oxycyte
®
 
cytotoxicity investigation may finally answer whether it can be totally trusted as safe for 
BAL systems. 
Due to the versatile capabilities, the simulation work in CHAPTER 4 did not only 
aim to find a solution for previous bioreactor O2 delivery issue, but also to characterize 
why the gelatin sponge scaffold let cells generate different function results than collagen 
gel, e.g. albumin secretion (Fig. 4.10). Simulated results entails that RPHs in gelatin 
sponge receive O2 as if they are in free O2-saturated aqueous medium (according to the 
high local O2 diffusivity) or as if the flow rate was doubled to offer more agitated 
convection and amplified O2 conditions (Fig. 4.9). 
Advantage of the gelatin sponge shown in CHAPTER 3 and 4 was again applied 
in CHAPTER 5, specifically focusing on experimentally how this ECM and its 
accompanied flow device (modified version) could support more cells and enhance their 
drug metabolism performances. CHAPTER 5 utilized RPHs not only because they are 
non-proliferative primary cells, but also they are known to be far more superior in drug 
biotransformation function than HepG2 cell line (same presumably applied to C3A cell 
line too) [103]. Of the two enzymes tested, the effect of gelatin sponge and flow 
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perfusion for ECOD enzyme was clear: more O2 entering cellular space enabled by such 
biomaterial which is believed help cells to achieve higher ECOD enzyme activity. For the 
other enzyme – EROD – the effect of improvement was clear in static culture. While the 
adverse effect in tube flow device appeared, it is believed that this function suppression 
was caused by the 3-MC increment per unit cell population during circulating medium 
scale-up. A fact that supports this hypothesis is that when 12-well plate sandwich C3A 
cell culture (initially 10
5
 cells/well) used the original 3-MC concentration (5 µM) in 
original EROD assay protocol (initially 15×10
5
 cells per well in 96-well plate) [71], very 
poor cell viability under confocal microscope, poor resazurin assayed metabolic activity 
as well as very weak EROD’s resorufin signal reading were found. It was found also that 
cell viability rose back to normal level when the 3-MC concentration for 12-well plate 
culture was adjusted down to 2 µM. This protocol adjustment suggests that the absolute 
3-MC amount per cell, instead of a fix concentration, should be consistent during 
medium volume scaling for minimizing cytotoxicity and resultant cell death. It is 
speculated further diluted 3-MC concentration will allow the flow device to demonstrate 
its effect to EROD activity as it did in ECOD. 
Overall, this dissertation explored several innovative engineering approaches to 
further enhance O2 delivery in hepatic devices fundamentally, including both 
experimental and numerical methods. These efforts, very important as the author 
considers, would directly contribute to better BAL design and functioning, and have 
profound impacts to the future development of this medical device. 
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6.1 Remarks for Future Work 
For the future of medical device BAL, the fundamental O2 enhancement studies 
contribute to BAL under trial progressing to ultimate FDA approval and market entry. 
Although there were decades of BAL development, today its medical application status 
still staggers in clinical trial. It appears that the route toward maturity of BAL is a long 
march. For example, one outstanding problem comes from selecting an optimal BAL cell 
source, and as of date there is no definitive answer yet: human primary hepatocytes are 
very limited for mass production; animal primary hepatocytes give concern of 
transferring zoonosis (e.g., Porcine Endogenous Retrovirus transmission), while 
hepatoma-derived cell lines (e.g. C3A cells) have efficiency issues and potential risk of 
tumorigenicity, and differentiating stem cells into hepatocytes is still extremely difficult 
so far [4, 8, 68, 142, 143]. 
There are other noticeable stem cells research updates, applicability of which 
BAL researchers would like to review: On June 8
th
, 2012, in Japan “a team at Yokohama 
City University, led by Professor Hideki Taniguchi, successfully transplanted induced 
pluripotent stem (iPS) cells into the body of a mouse, and then they began to grow into a 
human liver” [144, 145]. With a final scientific publication pending to formalize this 
report, options for BAL cell sources had already been recognized open to stem cells 
though cost is high and other in vitro differentiation restrictions apply [146]. Using 
autologous iPS cells can avoid the bioethical issue that using the allogeneic embryonic 
stem cells has. Either growing into a real human liver replacement for transplant patients, 
or serves as BAL’s cell source for solving availability issue, stem cells from appropriate 
sources might be the key to the solution for final organ replacement. 
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The initial work that is deemed for characterizing BAL feasibility for liver drug 
metabolism occurred in the 1980s [147] and this development is still undergoing [14, 
148-150]. Regarding such a particular category of function re-establishment in vitro, 
similar questions of cell source choice as testing model has been discussed [104, 151-
155], and a very informative broad comparison between human hepatic cell line and 
primary hepatocytes has been reported [156]. Just as the clinical application for BAL, 
many questions from this aspect of BAL usage remain to be answered by extensive 
studies, which will necessarily take significant labor, funds and time. 
To conclude this dissertation, regarding all aforementioned BAL imperfections, it 
is speculated that there will be still years before applying this therapeutic apparatus into 
reality and commercialization. Length of this duration is determined by the entire liver 
tissue engineering community and fundable resources. Before that day comes, the 
combining e engineering effort for BAL development should not be given up. 
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APPENDIX A: COURANT-FRIEDRICHS-LEWY CONDITION AND PROPERTY 
VALUES USED IN SIMULATION 
Courant-Friedrichs-Lewy condition is a necessary condition for numerically 
solving partial differential equations (usually hyperbolic) to obtain correct results. The 
mathematical form of this condition is stated as: 
      ( A.1 )  
where   is a constant.     is the courant number as quantitative index of CFL condition. 
In 3D case it is defined as: 
       (
 
  
 
 
  
 
 
  
) ( A.2 )  
where    is time step,          are components of computational grid dimension and 
      are velocity components at       direction respectively. Larger Courant number 
enables faster convergence speed yet less numerical stability, making it essential to 
choose its value wisely. From Eqn. A.2, with dynamic velocity development (varying 
     ) in stationary grids (unchanged         ), throttling Courant number as constant 
will make time step an irrational number. It natively lacks precise control in saving data 
at interested “integral flow time” such as 30 seconds or 5 minutes. The transient mode 
computation took more than 30 days by three octo-core 2.93GHz Intel
®
 Xeon
®
 X5570 
CPUs from a High Performance Computing (HPC). Simulated physical time progressed 
to 335s yet still failed to converge. 
Ideally, the free-surface featured 4QB should incorporate air-medium O2 
exchange for rich O2 content in air overwhelms O2 in aqueous medium and endows a 
strong air-to-medium O2 boundary condition at the interface. Yet the interfacial O2 
diffusivity across the two phases is not well defined and the direct numerical simulation 
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of the interfacial mass transport is very complicated [157] in terms of both theory 
derivation and code development. Even the diffusivity is immediate, continuous air-to-
medium O2 supply renders mass imbalance of the air phase, which pleads special 
programming treatment to supplement mass loss of air phase in FLUENT. While it 
remained hard to directly model interfacial diffusion and to calculate dynamic free 
surface at high computational cost thereof. 
Tab.A.1 lists the key values used in model simulation of CHAPTER 4. 
 
TABLE.A.1 Values of key properties used for parameters in simulation model of 
CHAPTER4. 
Symbol Description Value Unit Source 
   rat hepatocytes intracellular 
O2 diffusivity 
0.25 10
-9 
m
2
/s [121] 
   effective O2 diffusivity in 
porous collagen 
1.48 10
-9 
m
2
/s calculated 
   effective O2 diffusivity in 
gelatin sponge 
2.88 10
-9 
m
2
/s calculated 
   O2 diffusivity in free 
medium 
2.92 10
-9 
m
2
/s [121] 
   collagen permeability 
(1.3mg/mL) 
1.536 10
-14
 m
2
 [114] 
   gelatin sponge Darcy 
permeability 
9.04 10
-11
 m
2
 measured 
   Michaelis-Menten constant 3 mmHg [108] 
   PTFE membrane Darcy 
permeability 
1.48 10
-14
 m
2
 measured 
 ̇ medium mass flow rate 1.00967 10
-3
 kg/s previous 
setup[106] 
   O2 hydrodynamic radius 1.695 10
-7
 m [115] 
 ̇ medium volumetric flow 
rate 
1 cm
3
/s previous 
setup[106] 
   Boltzmann constant 1.38 10
-23 
J/K - 
(Continued) 
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(Continued) 
   medium density 1.00967 10
3
 kg/m
3
 [121] 
  temperature 310.15 K incubator setup 
  collagen fiber diameter 1~1.5 nm [158] 
  collagen fiber diameter 6.5 nm [159] 
  average pore size 
(collagen gel) 
3.5 µm deduced from 
[80, 115] 
  average pore size 
(gelatin sponge) 
350 µm averaged from 
[80] 
  gravitational acceleration 9.81 m/s2 - 
   PTFE membrane thickness 30 µm vendor 
  porosity of collagen gel (1.3 
mg/mL),       
0.929±0.013 - measured 
  porosity of gelatin sponge, 
      
0.956±0.003 - measured 
  medium dynamic viscosity 7.02326 10-7 kg/(m∙s) measured 
  saturated O2 mass fraction 
in aqueous medium at 37ºC 
and 1 atm 
6.636 ppm (10
-6
) [21] 
  collagen fiber volume 
fraction (1.3 mg/mL) 
0.0708 -  −     
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APPENDIX B: FLUENT
®
 USER DEFINED FUNCTION (UDF) SOURCE CODE 
/*********************************************************************** 
UDF to precisely model oxygen consumption by C3A or primary hepatocytes within the 
collagen space of 4QB, cell population 4 million per cartridge 
Gengbei Shi, Ph.D dissertation, UNC Charlotte, 2012 
***********************************************************************/ 
  
 #include "udf.h" 
 #include "mem.h" 
  
 #define Km 3.  /*Michaelis-Menten constant, in mmHg*/ 
 #define n 8.54482e5 /* Hepatocytes cell density, 2million/m^3*/   
 #define Vmax 0.7286   /* Maximum hepatocytes O2 uptake rate in nmol/s-million cells 
*/ 
 #define Rho 32e-12 /* Oxygen molar mass in kg/nmol*/ 
 #define Alpha 3.1385e-5 /*Henry's constant in ml O2/mmHg-ml medium*/ 
  
 DEFINE_SOURCE(MM_O2source,c,t,dS,eqn) 
 {  
  real source; 
 real rho_o2 = 4.0625e-5; /* in kg/ml*/ 
 real rho_medium = 1.00967e-3; /*in kg/ml*/ 
   
 source = - Rho * Vmax * 2 * n * C_YI(c,t,0) / (C_YI(c,t,0) + rho_o2/rho_medium 
* Alpha * Km);  /* C_YI(c,t,0)is oxygen mass fraction, in kg O2/kg medium */ 
                 /* 4 million each cartridge*/ 
         /*convert ml o2/ ml medium into kg 
o2/ kg medium */ 
  
 return source; 
 } 
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/*********************************************************************** 
UDF to Define Density of Mixture (medium-dissolved O2) 
Gengbei Shi, Ph.D dissertation, UNC Charlotte, 2012 
***********************************************************************/ 
  
#include "udf.h" 
  
 
  
DEFINE_PROPERTY (mix_density, c, t) 
  
{ 
  real m_O_den = 1009.67; 
  
 return m_O_den; 
 } 
 
   
/*********************************************************************** 
UDF to set soluble O2 upper limit in medium, 4 cartridges 
Gengbei Shi, Ph.D dissertation, UNC Charlotte, 2012 
***********************************************************************/ 
 
#include "udf.h" 
 
DEFINE_EXECUTE_AT_END(execute_at_end) 
{  
 Domain *d = Get_Domain(1); 
 Thread *t = Lookup_Thread(d,14); 
 cell_t c; 
 thread_loop_c(t,d) 
 {  
      begin_c_loop(c,t) 
      if (C_YI(c,t,0)> 6.636e-6)   
      C_YI(c,t,0) = 6.636e-6; 
      end_c_loop(c,t) 
  } 
} 
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/*********************************************************************** 
UDF to distinct different O2 diffusivity in medium only and in collagen-medium space 
with cells presence, cell population 8 million per cartridge, 4 cartridges 
Gengbei Shi, Ph.D dissertation, UNC Charlotte, 2012 
***********************************************************************/ 
 
 #include "udf.h" 
 #include "mem.h" 
  
 #define FD_MEDIUM  2.92e-9 
 #define EFFD_MEDIUM_S 2.89e-9  
 #define EFFD_MEDIUM_C 1.48598e-9  
 #define DIFF_CELL 0.25E-9   /*unit m2/s */ 
 #define PHI 7.5e-9   /* rat hepatocytes volume per 10^6 cells*/ 
 #define N 8    /* rat hepatocytes population in 10^6 */ 
 
  DEFINE_DIFFUSIVITY(O2_diffusivity, c, t, i)   /* 0 as O2 index number, define O2 
diffusivity in free medium only*/  
 {  
  real O2_diff = FD_MEDIUM; 
  int zone_ID = THREAD_ID (t); 
  if (zone_ID == 14) 
  O2_diff = FD_MEDIUM;  /* unit m2/s */ 
  else if (zone_ID == 10 || zone_ID == 11 || zone_ID == 12 || zone_ID == 
13) 
  O2_diff = EFFD_MEDIUM_S*(1-(1-
DIFF_CELL/EFFD_MEDIUM_S)*(1.727*PHI*N-
0.8177*PHI*N*PHI*N+0.09075*PHI*N*PHI*N*PHI*N));   
  /*define O2 diffusivity in 2nd cell-collagen-medium space, where 0.01 is 
collagen hindering correction factor*/ 
  return O2_diff;   
 } 
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APPENDIX C: ANALYSIS OF SHEAR STRESS INTENSITY IN POROUS 
SCAFFOLD – A SIMPLIFIED APPROACH 
Since in any biodevices, increasing flow rate will increase both O2 supply and 
shear stress, the balance between these two must be considered under all circumstances 
and an optimal flow rate is desired. However, due to irregularity and randomness of 
scaffold microarchitecture, analytical prediction of shear stress of interstitial flow at 
designated locations is difficult and computational method must be referred. These 
computations either assumed interconnected and uniformly sized pore [160], or based on 
actual microcomputer tomography (µCT)-scanned geometry [161, 162], accuracy of both 
cases is to be yet corroborated. 
It would be pertinent to analyze the actual shear stress level in tube device for 
justifying the flow rate. A simple estimation can be achieved: the 15 mL conical tube has 
an inner diameter of 16 mm, making the cross-sectional area of the sponge disc inside as 
2 cm
2
, and the superficial fluid velocity (flow speed assumed uniform on cross-sectional 
area) through the sponge disc as 3.42 × 10
-3
 cm/s (given flow rate 0.41 mL/min in 
experiments). 
For simplification, a “straight lumen” model is used to represent tortuous channel 
in the porous material, and fully developed laminar flow velocity distribution in pipe can 
be used to estimate the wall shear stress at locations hepatocytes adhere to. (Fig. C.1) 
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FIGURE C.1. Simplifying cell embedded tortuous channel into straight lumen for stress 
analysis. 
 
 
 
The fully developed laminar flow velocity profile in a pipe is parabolic [110]: 
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(  −   ) 
( C.1 )  
Given constant viscosity, the 3D shear stress tensor is defined as: 
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where 𝑼 is velocity vector: 𝑼           and  𝑼 is the gradient tensor of velocity: 
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 ,  𝑼  is the transposed matrix of  𝑼. 
In the simplified axisymmetric lumen, assuming fully developed flow and 
incompressible fluid, density   is constant and dynamic viscosity   can also be regarded 
as constant at stable temperature (e.g., incubator chamber temperature 37°C). Thus Eqn. 
C.2 is simplified to: 
  − 
𝑑 
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2
 
  
  
 
( C.3 )  
where   is the flow velocity through the lumen, and   is lumen radius. Assume local 
pressure gradient equals to the total pressure gradient, by Darcy’s law it is: 
hepatocytes 
interstitial 
medium flow 
r=R 
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In a specified lumen, the minimum and maximum wall shear stresses by plugging 
in values of  ,  ̅,     ,      as well as   acquired from CHAPTER 4, are: 
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( C.6 )  
where 𝜈 is kinematic viscosity: 𝜈    ⁄ . 
The maximum stress, from this simplified analysis, did not exceed the shear stress 
benefit bound (0.5 Pa) with average flow rate at 0.41 mL/min (pump speed: 5 rpm), and 
moderately higher flow rate is more likely to provide ampler O2 than disturbing 
hepatocytes functionalities. However, in real pores due to tortuosity and varying 
diameters instead of “straight lumen with constant diameter”, the maximum shear stress 
in gelatin sponge should be higher than estimation above. Therefore, the speculation on 
flow rate is upon experimental verification. 
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APPENDIX D: SAMPLES OF CONFOCAL FLUORESCENT IMAGES FOR C3A 
CELLS VIABILITY STUDY IN CHAPTER 3 
   
FIGURE D.1 A fluorescently stained sample field of C3A cells sandwich-cultured in 12-
well plate using normal medium. LEFT: Calcein-AM stained cells that are effusive and 
not countable (live cells only); MIDDLE: Hoechst 33324 stained cells that are separated 
and countable (all cells); RIGHT: Ethidium homodimer stained cells (dead cells only). 
Objective 10×. 
 
 
 
  
FIGURE D.2 A fluorescently stained sample field of C3A cells sandwich-cultured in 12-
well plate using PFC-medium. LEFT: Hoechst 33342 stained cells; RIGHT: cells 
morphology at same field. Objective 20×, zoom 4×. This field had no ethidium 
homodimer stain mark (viability close to 100%). 
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FIGURE D.3 Two random sample fields of 100 µm sliced stained gelatin sponge-C3A 
cells assembly cultured in flow device using normal medium, where scaffold attached cell 
colonies can be discerned. LEFT: random field 1; RIGHT: random field 2. Objective: 10× 
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